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ABSTRACT
During development, the nervous system is a sensitive target for chemical
exposure in both humans and animal models, and early life-stage exposures can lead to
long-term effects on motor activity, sensory function, and cognition. Currently, there are
minimal to no developmental neurotoxicity (DNT) data available for thousands of
chemicals used in commerce, and it is impractical to screen these chemicals in rodent
models using the existing DNT test guideline, as this test is costly, time- and animalintensive, and low-throughput. Therefore, there is a recognized need to use alternative
non-mammalian models to support screening and prioritization of chemicals for DNT
testing, as well as hypothesis-driven studies that may help uncover mechanisms of DNT
for pesticides and understudied high-production volume chemicals in commerce. Using
zebrafish as an animal model, the objectives of this dissertation were to: 1) develop a
high-content screening (HCS) assay for rapid and cost-effective identification of potential
developmental neurotoxicants during zebrafish embryogenesis, and 2) begin investigating
the mechanism of action of abamectin – an insecticide identified as a positive hit in our
HCS assay – within zebrafish embryos. Data presented within Chapter 2 suggests that,
compared to existing zebrafish-based assays, our HCS assay provides a simpler,
streamlined discovery platform for identifying and prioritizing potential developmental
neurotoxicants with: 1) increased sample sizes; (2) broad concentration−response format;
(3) short assay duration (∼22 h total); and (4) minimal technical grade test material
needed for screening. Data presented within Chapter 3 suggests that 1) abamectin induces
v

rapid and reversible hypoactivity within early zebrafish embryos, 2) abamectin-induced
hypoactivity is blocked by pretreatment with γ-aminobutyric acid (GABA) antagonists,
and 3) zebrafish and mammalian ionotropic GABA receptor subunits are homologous –
suggesting that these findings may have relevance to rodent models and humans. Overall,
our findings suggest that zebrafish-based behavioral assays can be used within a tiered
regulatory toxicity testing framework to help screen and prioritize chemicals for DNT
testing in rodent models and develop hypothesis-driven studies in zebrafish embryos.
Therefore, our HCS assay, in combination with follow-up studies, provides a rapid, costeffective

method

for

identifying

and

characterizing

neurotoxicants, helping to fill the current DNT data gap.
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CHAPTER 1
INTRODUCTION
1.1 TOXICITY TESTING: CHEMICALS IN GLOBAL COMMERCE
Globally, thousands of industrial chemicals, including basic chemicals (e.g.,
petrochemicals, basic inorganics, polymers), specialty chemicals (e.g., pesticides, paints,
colorants), and consumer chemicals (e.g., detergents and soaps), are produced on a daily
basis (European Chemical Industry Council, 2014). From 2002 to 2012 alone, total world
chemical sales doubled from $2.338 trillion to $5.364 trillion (European Chemical
Industry Council, 2014). In the United States (US), the Toxic Substances Control Act
(TSCA) regulates domestic manufacturing and importation of chemical substances and
mixtures. One group of chemicals that are exempted from this law is pesticides, which
are regulated under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) (US
Environmental Protection Agency, 2002a, 2008). However, as pesticides are designed to
be biologically active and cause harm to insects, plants or other living things, laws
regulating pesticides are much stricter than those regulating industrial chemicals.
Originally enacted in 1947, FIFRA calls for the Environmental Protection Agency (EPA)
to ensure that a registered pesticide will not have “unreasonable adverse effects on
humans and the environment” (Lolley, 1990). To register a pesticide, the registrant is
required to conduct many studies to assess the safety of the chemical, and the EPA is left
to determine whether the pesticide meets the safety standard. Since its establishment this
law has undergone many amendments, and as a result of the Food Quality Protection Act

1

of 1996, pesticides are under continuous review by the EPA and go through a
reregistration process every 15 years. This ensures that, if new concerns are raised due to
recently published data, the pesticide will get reevaluated for use (Lolley, 1990). TSCA,
on the other hand, was written in 1976, and approximately 62,000 chemicals in
commerce were “grandfathered” under this law. Under TSCA, these chemicals are
considered “existing” chemicals, which can remain in commerce unless the EPA is able
to demonstrate a potential for hazard. In other words, these “existing” chemicals are
presumed “safe” until there is reason to believe they are dangerous. “New” chemicals
under TSCA are those that are being introduced into commerce for the first time, or
existing chemicals that are being registered for a new use. For new chemicals, EPA relies
on the manufacturer to test the chemical, and, though the responsibility to determine
whether the chemical poses a human or environmental health risk is on the manufacturer,
there are no specific toxicity testing requirements (Locke and Myers, 2010). Therefore,
even today, the majority of chemicals on the TSCA Inventory, which is now over 84,000,
still have not been assessed for potential health and/or environmental impacts.
The increase in global chemical production is, to some degree, driven by the
redistribution of chemical production in markets around the world. Due in part to the
economic recession in 2007 and its larger impact on developed countries, developing
countries have begun to emerge as leaders in the chemical industry. While the European
Union (EU) and North American Free Trade Agreement (NAFTA) countries reported 18
and 17% of total global chemical sales in 2012, over 50% of the total world chemical
sales were from Asia. China alone accounted for over 30% of these chemical sales, and
chemical production in the rest of Asia is on the rise as well (European Chemical
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Industry Council, 2014; Volz and Elliott, 2013). Currently, the only chemicals in
commerce regulated under TSCA include the final chemical-containing products that are
imported into the United States, as well as domestically manufactured chemicals. This
means that potential risks within these developing countries where chemical production
occurs are not considered, and in most cases, regulations on basic chemical safety within
these countries are less stringent and unenforced, providing an unfair risk for these
disadvantaged populations (Volz and Elliott, 2013). In addition, there are a handful of US
chemical companies attempting to maintain their competitive advantage by shifting their
chemical production to Asia and Latin America, expanding their global strategies
(KPMG International, 2010). Therefore, there is a recognized need to balance risk to
account for inconsistent standards in regulations from industrialized to developing
countries.
This continuous rise in chemical production and sales and redistribution
creates much concern about the minimal amount of safety data available for these
chemicals. In addition to variation in written regulations for registering industrial
chemicals vs. pesticides within the US, this has drawn a lot of attention to the current
state of TSCA. In 2007, the EU implemented the Registration, Evaluation, Authorisation,
and Restriction of Chemicals (REACH) Regulation for management of chemicals in
commerce, which made it a requirement for safety data to be submitted for new and
existing chemicals produced in or imported into the EU (Vogel and Roberts, 2011). As
there is no distinction between new and existing chemicals under this law, all chemicals
produced or imported in “sufficient” quantities (at least 1 metric ton/year) have to be
assessed for health and safety by 2018 (Egeghy et al., 2011; Kvinge, 2011). This
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regulation shifts the responsibility of data generation and risk assessment for all
chemicals to industry rather than government authorities. The implementation of REACH
in the EU has created many initiatives for moving forward with reform of the TSCA.
Although two bipartisan bills have been proposed, one from the Senate (Chemical Safety
Improvement Act) and one from the House of Representatives (Chemicals in Commerce
Act), there is a lot of controversy over the amendment of the TSCA bill (Locke and
Myers, 2011). Ideally, a new federal statute would require evaluations for all chemicals in
active commerce and allow EPA to require safety testing without having to show
potential hazard prior to issuing a testing request. Generating toxicity data for the 84,000
chemicals regulated under the TSCA is not only a huge burden for the EPA, but it is also
very costly and impractical to generate toxicity data using traditional methods, such as
those used for the FIFRA, to determine risk for these chemicals (Locke and Myers,
2010).

1.2 HUMAN HEALTH RISK ASSESSMENT
Within the current framework used primarily for chemicals regulated under
FIFRA, risk assessment comprises three main components: hazard identification,
exposure assessment, and risk characterization. Within hazard identification, animal
bioassays are used to identify the potential harmful effects of a contaminant. Toxicity
tests conducted during the hazard identification process are divided into two main types:
non-cancer and cancer. Currently, non-cancer endpoint hazard identification toxicity tests
rely primarily on conventional animal bioassays that use rodent models. The required
toxicity tests include various acute, subchronic, and chronic studies that assess oral,

4

dermal, and inhalation toxicity, eye and dermal irritation, skin sensitization, and
neurotoxicity. Prenatal developmental toxicity and reproduction and fertility effects also
must be assessed, as well as metabolism, pharmacokinetics and immunotoxicity (Office
of Chemical Safety & Pollution Prevention, 2013). After the initial data requirements are
submitted to the EPA, a pesticide can be fully registered, conditionally registered, or
rejected. If there is reason to believe that more toxicity testing is needed, a pesticide can
be conditionally registered and more data may be solicited before full registration is
considered (US Environmental Protection Agency, 2015).
During exposure assessment, health risks are predicted based on the
frequency, magnitude, and duration of acute, sub-chronic, or chronic exposures. First, the
intake or uptake of the chemical contaminant from contact with air, water, house dust,
soil, or other sources is quantified, and then the internal or delivered dose of the parent
chemical or metabolite at the target organ is predicted using pharmacokinetic models (US
Environmental Protection Agency, 2012). To characterize risk, the no observed adverse
effect level (NOAEL) endpoint from acute, sub-chronic, or chronic toxicity studies is
used, and uncertainty, or safety factors, are applied to account for genetic variation in
human-to-human extrapolation, animal-to-human extrapolation, and other factors to
generate a reference dose (RfD). The RfD is then divided by the average daily dose
(ADD) estimated for human exposure to determine the level of concern (%RfD) for a
single contaminant or single exposure pathway. During risk characterization, an
additional uncertainty factor is generally applied for infants and children to take into
account potential differences in susceptibility such as pre- and post-natal toxicity. If the
%RfD is greater than 100%, a chemical is considered to be a concern. However, because
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of the assumptions made in using uncertainty factors, there is potential for the %RfD to
be over or underestimated (US Environmental Protection Agency, 2002b).

1.2.1 CURRENT REGULATORY TOXICITY TESTING PARADIGM
For decades, conventional toxicity tests that rely on mammalian models have been
used to predict toxicity and for estimating risk. The major advantage of the traditional
testing strategy is that there are known genetic and physiologic similarities between
rodents and humans. Although ideally a combination of studies on animal and human
models would provide the best and most informative data for assessing risk, most of the
time it is difficult to obtain data for hazard assessment of specific chemicals in humans.
In addition, human exposure information may be limited and unknown environmental
factors may cause uncertainties (US Environmental Protection Agency, 1998). The
availability of different rodent strains allows for genetic variation in susceptibility to be
accounted for; however, this also generates concern about which strain is the most
appropriate for testing a broad range of chemicals.
Unfortunately, the current toxicity testing paradigm is unable to provide
information for a large number of chemicals in commerce. For example, only five
industrial compounds have been listed as developmental neurotoxicants: lead,
methylmercury, polychlorinated biphenyls, arsenic, and toluene (Grandjean and
Landrigan, 2014), suggesting that either the current traditional testing strategy is effective
at keeping harmful chemicals out of commerce or, more likely, the potential toxicity of
the majority of industrial compounds on the developing nervous system has not been
adequately characterized or tested at all (Knudsen et al., 2011). Although the use of
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traditional toxicity tests is advantageous in some ways, the drawbacks far outweigh the
advantages – it is costly, time- and resource-intensive, low-throughput, does not allow for
various life stages to be tested, and generally relies on a crude endpoint that does not
allow mechanisms of toxicity to be explored. Due to these drawbacks and the high
demand to obtain toxicity data for thousands of chemicals in commerce regulated under
TSCA, there has recently been a push for a “new normal” for toxicity testing, shifting the
paradigm to using computational toxicology, cell-free and cell-based assays, and nonmammalian animal models for screening and prioritizing chemicals for testing in rodent
models. There has been a recognized need for the development of rapid and cost-effective
high-content and high-throughput screening (HCS/HTS) assays that use small nonmammalian animal models such as zebrafish to help efficiently screen and prioritize these
chemicals for more low-throughput toxicity testing. The advantages of HCS/HTS assays
compared to low-throughput assays are that they often times contain much larger sample
sizes and require little technical material. These types of assays can be designed to not
only assess morphological endpoints, but also multiple functional endpoints, providing
detailed information on how a chemical affects survival and body size, as well as give
insight into the potential mode of action (Leet et al., 2014; Yozzo et al., 2013).
Information gained from these studies can help identify the most important endpoints of
interest for mammalian studies as well as the chemical concentrations to use.

1.3 DEVELOPMENTAL NEUROTOXICITY (DNT)
In today’s world, more than 96% of manufactured consumer goods and products
are directly tied to the US chemical industry (American Chemistry Council, 2014). It is
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well known that the general population is exposed to many chemicals throughout their
lifetime, including potentially neurotoxic chemicals (US Environmental Protection
Agency, 1998). In recent years, an increase in the prevalence of neurodevelopmental
disorders, such as autism, attention-deficient hyperactivity disorder, dyslexia, and others,
has lead to a growing interest in the potential risks of neurotoxic chemical exposure
during early life-stages and the resulting effects on human health (US Environmental
Protection Agency, 1998). Although a percentage of these can be attributed to genetic
factors (30-40%), it is suspected that social and environmental factors are also involved.
In fact, evidence has demonstrated that an increased risk of attention-deficient
hyperactivity disorder has been linked to prenatal exposures to manganese,
organophosphate insecticides, and phthalates in drinking water, and an increased risk of
autism spectrum disorder has been linked to air pollution in California (Grandjean and
Landrigan, 2014).
Developmental neurotoxicity is defined as exposure to a chemical, physical, or
biological agent that occurs during development and results in an adverse change in the
structure or function of the central and/or peripheral nervous system (Giordano and
Costa, 2012). It is well known that the developing nervous system is a sensitive target for
chemicals in both human and animal models (Giordano and Costa, 2012; Grandjean and
Landrigan, 2006). Early life-stage exposures have the potential to result in alterations in
brain development and maturation, causing irreversible functional effects early on or in
later life stages (Grandjean and Landrigan, 2014; Jacobson-Kram, 2001). Throughout
development, the fetus is not well protected from exposure to environmental toxicants.
Detoxifying mechanisms are not completely functional, chemicals can cross the placenta
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into the bloodstream, and the blood-brain barrier is not completely formed in the early
stages, providing only partial protection (US Environmental Protection Agency, 1998).
Levels of exposure much lower than the concentrations known to adversely affect adults
may cause permanent damage in the brain during early development (Grandjean and
Landrigan, 2014; Jacobson-Kram, 2001).
One well-known chemical that has been shown to cause DNT in children at much
lower levels than the levels that cause neurotoxicity in adults is lead. Lead was first used
in paints in the 1800s, and then in gasoline beginning in the 1920s (Giordano and Costa,
2012). In adult humans, lead exposure primarily occurs within the workplace, and the
most common resulting clinical effect is peripheral neuropathy, which occurs when lead
levels in blood are approximately 60 µg/ml. However, this effect is reversible using
chelation therapy. At higher lead concentrations in the blood (100 µg/ml), colic,
paralysis, serious motor effects, and, in severe cases, brain disorders, can occur
(Giordano and Costa, 2012; Needleman, 2004). In the 1970s, the maximum acceptable
blood level for lead in children was 60 µg/dl, as it was based on the level associated with
clinical signs of toxicity in adults. Although the first described case of lead poisoning in
children in the US was in 1914, it wasn’t until the 1970s that a better understanding of the
developmental neurotoxic effects of lead became apparent. During this time, a handful of
major epidemiological studies began to show associations between body burden of lead
in children and lower academic performance and shortened attention span, in the absence
of clinical signs of acute toxicity. These data lead to regulatory changes, including
lowering the level of concern in children from 60 µg/dl to 10 µg/dl and the phasing out of
lead gasoline and paint. By 1991, blood levels of lead in children had dropped
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significantly. Even so, in the absence of signs of acute toxicity, associations between
blood lead levels of 2 µg/ml and decreased academic performance and other behavioral
effects have still been observed (Giordano and Costa, 2012). Similar behavioral
alterations, cognitive defects and impaired learning abilities have also been observed in
animals such as rodents and primates (Needleman, 2004).

1.3.1 HISTORY OF THE DNT GUIDELINE
In addition to lead, methylmercury was also recognized as a developmental
neurotoxicant in the mid-1950s when children of mothers living around Minamata Bay
who consumed methylmercury-contaminated fish were found to exhibit neurological
deficits (Giordano and Costa, 2012). In subsequent years, there were more than 500
registered pesticides with varying active ingredients and potencies, the majority of which
targeted the nervous system of insects. It was also estimated that 3-28% of all chemicals
were thought to have neurotoxic potential (US Environmental Protection Agency, 1998).
In the early 1960’s, publications that examined the effect of chemicals on behavioral
function in young and adult animal models began to emerge. During this time period,
there were also more than 500 registered pesticides with varying active ingredients and
potencies, the majority of which targeted the nervous system of insects. In addition, it
was estimated that 3-28% of all chemicals were thought to have neurotoxic potential (US
Environmental Protection Agency, 1998). The extensive evidence in the scientific
literature evaluating chemical effects on the development and function of the nervous
system provided a strong foundation for development of a DNT guideline. Collaborative
studies within and across laboratories worldwide began to evaluate the validity,
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reliability, and variability of these behavioral tests and, by 1986, a DNT guideline was
established within the US for specific solvents. However, it wasn’t until 1991 that this
guideline included evaluation of toxic substances and pesticides. In 1998, the US EPA
DNT guideline was revised as part of an effort to harmonize guidelines within the US
EPA and OECD. In 1995, an OECD Working Group recommended the development of
OECD Test Guideline 426 (Developmental Neurotoxicity), and after multiple revisions, it
was finalized in 2007 (Makris et al., 2009).
Test

Guideline

426:

Developmental

Neurotoxicity

(http://www.oecd-

ilibrary.org/environment/test-no-426-developmental-neurotoxicity-study_978926406739
4-en) assesses the potential effects of pre- and postnatal chemical (mainly pesticide)
exposure on the morphology and function of the developing nervous system within
preweaning, adolescent, and young adult rodents (Organization for Economic Cooperation and Development, 2007). This assay evaluates the potential for DNT using a
series of physical and developmental landmarks and a range of functional/behavioral
endpoints comprising motor activity (including habituation), motor and sensory function,
and cognitive function (learning and memory) (Organization for Economic Co-operation
and Development, 2007). Commonly used strains of rats are preferred for the DNT
guideline, and a minimum of 20 litters per treatment group and 3-4 dose levels plus a
vehicle control are needed for successful study completion. Therefore, assuming an
average litter size of 8-12 pups, each DNT study requires 640 to 1200 rats (excluding
dams) per chemical. Exposure of pregnant female rats to a chemical occurs at minimum
from gestation day (GD) 6 (implantation) through lactation (post-natal day (PND) 21),
and DNT tests are conducted on the offspring periodically from about PND 4 (sometimes
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earlier) through PND 60-70 to assess select endpoints within young adult rats
(Organization for Economic Co-operation and Development, 2007). This test, although
not routinely required by regulatory agencies in the US, is required if other information
indicates the potential for DNT. According to the EPA, this toxicity test must be
completed using a weight of evidence approach if “the pesticide (i) causes treatmentrelated neurological effects in adult animal studies, (ii) causes treatment-related
neurological effects in developing animals, following pre- and postnatal exposure, (iii)
elicits a causative association between exposures and adverse neurological effects in
human epidemiological studies, (iv) evokes a mechanism that is associated with adverse
effects on the development of the nervous system” (US Government Publishing Office
and Office of the Federal Register, 2012).
Recent evidence suggesting an association between neurodevelopmental disorders
and chemical exposure emphasizes the lack of DNT data available for chemicals
regulated under TSCA, as it is estimated that only about 200 (2%) of the 84,000
chemicals on the TSCA Inventory have undergone DNT testing (Giordano and Costa,
2012). In addition, it is has been shown that DNT studies can provide information about
sensitive neurobehavioral endpoints in offspring that are not examined in any other
required test guideline, highlighting its value as a sensitive endpoint and usefulness as a
valuable source of data for risk assessment (Makris et al., 2009). However, it is
impractical to use the existing DNT test guideline to test these chemicals, as this test is
costly, time-intensive, and low-throughput. For a single chemical, this test can take up to
one year and cost $1 million. Due to these costs and a lack of regulatory demand, only
about 90 chemicals have been tested in the last decade (Crofton et al., 2012). Although

12

significant advancements in assays that use alternative non-mammalian models have
occurred over the last 5-10 years, a large majority of assays relevant to DNT are focused
on key molecular and cellular events in vitro and, as such, do not address the potential for
chemically-induced DNT within an intact organism (Coecke et al., 2007; Crofton et al.,
2011). Therefore, there is a recognized need to use alternative non-mammalian models to
support screening and prioritization of chemicals for DNT testing and to help uncover
mechanisms of DNT for pesticides and understudied high-production volume chemicals
in commerce (Coecke et al., 2007; Crofton et al., 2011).

1.4 ZEBRAFISH AS A MODEL FOR EARLY NEURODEVELOPMENT
Zebrafish have been used as a model to study vertebrate neurodevelopment for
over 30 years (Eisen et al., 1989; Westerfield et al., 1990), and, as a result, the nervous
system circuitry within zebrafish is well characterized and understood (Myers, 1986;
Westerfield, 1986). Neural tube formation and central nervous system development in
zebrafish occurs during the segmentation period (10−24 hours-post-fertilization (hpf))
(Kimmel et al., 1995). By 18 hpf (18-somite stage), the anterior neural tube develops into
ten distinct brain neuromeres while the posterior neural tube develops into the spinal cord
(Kimmel et al., 1995). Primary interneurons differentiate and extend their axons in a
relatively simple pattern within each brain neuromere and spinal cord segment.
Throughout development, neurons within the spinal cord are continually integrated into a
functional network of circuits, producing a series of locomotive behaviors (Knogler et al.,
2014). Primary motoneurons, although born during late gastrulation (9-10 hpf), begin to
extend their axons from the spinal cord around 18 hpf, innervating target axial muscles in
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a highly stereotyped, error-free manner (Myers, 1986). This results in the initiation of
weak, spontaneous muscle contractions within the developing embryo (Kimmel et al.,
1995). This spontaneous behavior can be classified into two groups: single coils and
double coils (Knogler et al., 2014). The initial spontaneous contractions consist of single
coils, where, after a single contraction of the trunk, the tail returns to its resting position.
Double coils begin about six hours after single coils and consist of two contralateral
contractions of the trunk within one second. Two other locomotive behaviors also occur
sequentially within zebrafish during development – touch-evoked coils, which begin at
21 hpf and organized swimming, which begins at 27 hpf (Saint-Amant and Drapeau,
1998). By 24 hpf, the nervous system is fully functional, allowing for rapid assessment of
neurotoxicity using these neurobehavioral endpoints within less than 30 hours after
exposure initiation.
Zebrafish embryogenesis occurs rapidly, ex utero and consists of seven welldocumented developmental stages: zygote (0-0.75 hpf), cleavage (0.75-2.25 hpf), blastula
(2.25-5.25 hpf), gastrula (5.25-10 hpf), segmentation (10-24 hpf), pharyngula (24-48
hpf), and hatching (48-72 hpf) (Kimmel et al., 1995). Due to the small size and
transparency of zebrafish during embryogenesis, the potential for adverse effects on the
developing nervous system can be readily evaluated at both the morphologic- and
functional-level. For instance, the notochord, spinal cord, or brain can be imaged in vivo,
and locomotive behaviors – indicators of effects on the nervous system – can be assessed
within 96- or 384-well plates (Lee and Freeman, 2014). Females produce hundreds to
thousands of embryos providing a large sample size, which is especially beneficial for
HCS/HTS assays. The zebrafish genome is fully sequenced, and approximately 70% of
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human genes have at least one zebrafish orthologue (Howe et al., 2013). Furthermore,
orthologous genes with key regulatory roles in neural development are also functionally
conserved; therefore, neurotoxic chemicals that affect zebrafish neural development are
likely to also affect human neural development. Established transgenic lines can be used
for live imaging of the nervous system, and immunohistochemistry techniques can be
used to label neurons and axons within developing zebrafish embryos (Higashijima et al.,
2000; Trevarrow et al., 1990). Moreover, compared with other larger vertebrate models
like rodents, the costs associated with start-up and maintenance of zebrafish colonies are
minimal and requires significantly less personnel labor and laboratory space. Due to these
advantages, zebrafish have emerged as an in vivo alternative non-mammalian model for
DNT testing to help screen and prioritize chemicals for rodent assays (Lee and Freeman,
2014). In fact, zebrafish have become a popular vertebrate model for studying the
developmental basis of human diseases such as autism, schizophrenia and others (Morris,
2009; Tropepe and Sive, 2003).

1.4.2 THE NEED FOR DNT-SPECIFIC HCS/HTS ASSAYS
Several zebrafish-based DNT studies have relied on neurobehavioral alterations
as a neurotoxicological endpoint. For example, locomotion assays using zebrafish have
been used to examine spontaneous tail contractions, touch-response, and/or swimming
patterns in response to chemical and/or light stimuli in microplate format (Irons et al.,
2010; Kokel et al., 2010; Stanley et al., 2009). One study also demonstrated that
behavioral alterations after exposure to a set of ten compounds including known
developmental neurotoxicants were comparable to existing mammalian data (90%
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agreement overall), supporting the use of early life-stage zebrafish to predict chemicallyinduced DNT within higher organisms (Selderslaghs et al., 2013). Although valuable for
providing information on behavioral responses following developmental exposure, these
assays can be complex, requiring treatment solution renewals (and, therefore, more
technical material), excessive embryo/larval handling, and cost-prohibitive infrared
cameras needed for imaging under dark conditions. Moreover, conventional zebrafishbased locomotive assays are conducted using a larval stage (6-7 days post-fertilization
(dpf)) that is protected by animal use regulations around the world, likely resulting in
minimal animal use reductions for DNT testing (Irons et al., 2009; Padilla et al., 2011).
In recent years, there has been some discontinuity in toxicity results present
among current zebrafish studies, which is likely due to variations in test methods across
different laboratories due to complex experimental designs. Therefore, despite significant
advancements in zebrafish locomotion assays, rapid and streamlined HCS assays are still
needed to facilitate screening and prioritization of chemicals for DNT testing within
rodents. More simplified, efficient toxicity tests would improve the variation observed in
test results across academic labs, and provide a uniform way to screen compounds with
consistent results. Therefore, this dissertation is focused on using spontaneous tail
contractions – the first sign of locomotion in zebrafish embryos – as a rapid, costeffective endpoint amenable for identification of potential developmental neurotoxicants.

1.5 RESEARCH OBJECTIVES
As discussed above, there is a need to predict the potential for DNT for
thousands of untested chemicals used in commerce without using conventional animal
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bioassays. Alternative animal models can provide a rapid, cost-effective alternative
method for screening and prioritizing chemicals for resting in rodents, as well as
identifying the molecular mechanisms of neurotoxicity for these chemicals. Using
zebrafish embryos as a model for studying the developing nervous system, the first part
of this dissertation (Chapter 2) focuses on developing a 384-well-based HCS assay for
identification of potential developmental neurotoxicants using spontaneous activity as a
behavioral readout. Subsequently, the second part (Chapter 3) aims to begin investigating
the mechanism of action of abamectin – a potent avermectin insecticide identified as a
positive hit in the HCS assay described within Chapter 2 – within zebrafish embryos.
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CHAPTER 2
HIGH-CONTENT SCREENING ASSAY FOR IDENTIFICATION OF CHEMICALS IMPACTING
SPONTANEOUS ACTIVITY IN ZEBRAFISH EMBRYOS
2.1 INTRODUCTION
In addition to animal use considerations, it is impractical to screen the thousands
of untested chemicals in commerce using the existing DNT test guideline, as this test is
costly, time-intensive, and low-throughput. Furthermore, in recent years, there has been
an increase in the number of emerging contaminants of concern, such as pharmaceutical
and personal care products and nanomaterials, most of which have not been adequately
tested for potential toxic effects. Rapid and streamlined HCS assays that rely on
locomotor endpoints are needed to facilitate screening and prioritization of chemicals for
DNT testing within rodents. Therefore, for this study, we focused on spontaneous tail
contractions – the first sign of motor activity – within zebrafish embryos as a behavioral
endpoint amenable for identification of potential developmental neurotoxicants. Although
other assays (Kokel et al., 2010; Truong et al., 2013) have focused on this endpoint, the
HCS assay reported here provides a streamlined discovery platform with 1) increased
sample sizes; 2) broad concentration-response format; 3) short assay duration (~22 hours
total); and 4) minimal technical-grade test material needed for screening.
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2.2 MATERIALS AND METHODS
2.2.1 ANIMALS
For this assay, we relied on a robust line of transgenic zebrafish (fli1:egfp) that
stably express enhanced green fluorescent protein (eGFP) within vascular endothelial
cells (Lawson and Weinstein, 2002). This strain begins expressing eGFP at ~14 hours
post-fertilization (hpf), allowing us to accurately track spontaneous tail contractions in
the absence of shading effects observed under transmitted light. Adult fli1:egfp zebrafish
were maintained on a 14-h:10-h light:dark cycle within a Mini Mass Embryo Production
System (mini-MEPS) (Aquatic Habitats, Inc., Apopka, FL) containing a photoperiod light
cycle dome and recirculating conditioned reverse osmosis (RO) water (~27-28°C). Adult
females and males were bred either directly within the mini-MEPS, directly on-system
using in-tank breeding traps suspended within 3 L tanks, or off-system within a light- and
temperature-controlled incubator using breeding traps suspended within 1 L tanks. For all
experiments described below, newly fertilized eggs were staged according to previously
described methods (Kimmel et al., 1995). All fish were handled and treated in accordance
with approved Institutional Animal Care and Use Committee (IACUC) protocols at the
University of South Carolina – Columbia.

2.2.2 CHEMICALS
Chemicals were purchased from ChemService, Inc. (West Chester, PA) and
Sigma Aldrich (St. Louis, MO). Chemical names, chemical formulas, CAS registry
numbers, vendor, and purities are provided within Table A.1. Within 24 hours of test
initiation, stock solutions of each chemical were prepared by dissolving chemicals in high
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performance liquid chromatography (HPLC)-grade dimethyl sulfoxide (DMSO) (50
mM), and then performing two-fold serial dilutions into DMSO to create stock solutions
for each working solution. All stock solutions were stored at room temperature within 2
mL amber glass vials containing polytetrafluoroethylene (PTFE)-lined caps. For each
individual plate, working solutions of all treatments were freshly prepared by spiking
stock solutions into embryo media (EM) (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2,
0.33 mM MgSO4), resulting in 0.1% DMSO within all vehicle control and treatment
groups.

2.2.3 HIGH-CONTENT SCREENING (HCS) ASSAY
Exposure setup. Black 384-well microplates containing 0.17-mm glass-bottom
wells (Matrical Bioscience, Spokane, WA) were used for this assay. Newly fertilized
eggs were collected immediately after spawning and placed in groups of approximately
50 per glass petri dish within a light- and temperature-controlled incubator until 5 hpf.
Although dechorionation may help decrease uncertainties regarding uptake across the
chorion, previous attempts within our laboratory to dechorionate embryos prior to
exposure resulted in unacceptable survival within control embryos; therefore, chorionated
embryos were used for all exposures. Vehicle control (0.1% DMSO) or treatment
solution (50 µL per well) was added to odd columns of a 384-well plate at 5 hpf. Using
clean forceps, 192 viable fli1:egfp embryos were then manually arrayed into the plate
over a 20-minute time period, resulting in one embryo per well and 16 initial embryos per
column. Each plate was checked to ensure that all embryos were intact or undamaged
following loading. Initial attempts to use 384 embryos were unsuccessful due to
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increased imaging duration, resulting in variation in spontaneous activity within vehicle
control embryos across the plate (Figure A.1). For chemical screening assays, vehicle
control groups occupied two columns flanking the left and right sides of the plate
(columns 1 and 23) to account for potential control variance in spontaneous activity from
initiation to termination of image acquisition. The plate was then incubated at 28°C under
a 14-h:10-h light:dark cycle and static conditions until 24 hpf.
Image acquisition. At 24 hpf, the plate was removed from the incubator and
allowed to acclimate in a second incubator at 25ºC in treatment solution for 1 hour with
the lid removed. This acclimation was done to ensure that changes in temperature from
the incubator (28°C) to the imager (25°C) did not affect spontaneous activity, as previous
experiments have demonstrated that temperature alterations can affect this behavior
(Saint-Amant and Drapeau, 1998). The plate was then centrifuged for 3 minutes at 200
rpm to ensure that the majority of embryos were near the bottom of each well. Using an
automated image acquisition protocol (Figure 2.1) and parameters (Table A.2) optimized
for our ImageXpress® Micro (IXM) Widefield High-Content Screening System
(Molecular Devices, Sunnyvale, CA), each embryo was imaged in treatment solution
over a 6-second time period to assess the presence or absence of spontaneous tail
contractions. Image acquisition began within five to ten minutes after centrifugation,
commencing at well A01 and proceeding down each column across the plate from
column 1 to column 23. Throughout this process, one 6-second stream was acquired at a
time for each well. This time period was chosen to minimize variation in spontaneous
activity across the plate due to increased imaging duration. Image acquisition procedures
were identical for each independent plate. During the entire ~1.4-hour image acquisition
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period, internal temperature within the IXM system was maintained between 25-27°C by
removing panels on both sides of the IXM system and blowing air from left to right
through the IXM with a portable fan; internal temperature was monitored and recorded at
initiation and termination of imaging using a digital thermometer. In accordance with
National Institutes of Health (NIH) guidelines (National Institutes of Health, 2013),
embryos were then euthanized by placing the plate at -20ºC.
Data extraction. Custom journal scripts for video generation were developed
using MetaXpress® 4.0.0.24 software (Molecular Devices, Sunnyvale, CA). Prior to data
extraction, stream acquisitions within each well were inspected within MetaXpress to
assess survival. As heart morphogenesis is not complete until ~48 hpf, presence or
absence of heartbeat was not used as a criterion for survival. Rather, coagulated embryos
and embryos with undeveloped or absent tails were considered dead and were not
analyzed for total body area or spontaneous activity. Fully automated journal scripts were
used to generate videos of each well by converting each stream acquisition to an .AVI
file. Video file sizes were reduced within Format Factory (http://www.pcfreetime.com/)
by conversion to MPEG4 (DivX). Converted videos were then imported into EthoVision
XT 9.0 (Noldus Information Technology, Leesburg, VA) to determine the mobility state
of each embryo. Based on user-defined detection settings that identify the embryo as the
subject, embryos were considered highly mobile (exhibiting spontaneous tail
contractions) if the change in subject pixel area from one frame to another was above a
previously optimized user-defined threshold. Initial attempts to use EthoVision to
quantitatively assess the number of spontaneous tail contractions were unsuccessful due
to variation in this behavioral phenotype within individual control embryos (Figure A.3).
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Rather, EthoVision output was used to assign spontaneous activity values to each
embryo. Inactive embryos were defined as embryos that were immobile during the entire
6-second stream acquisition and were assigned an activity value of 0. Active embryos
were defined as embryos that moved for at least 0.1 second and were assigned an activity
value of 1. Within EthoVision, duration is assessed in 0.1-second increments; therefore,
we used this value as a criterion for activity in order to include embryos exhibiting partial
tail contractions as active embryos.
Automated custom journal scripts within MetaXpress® were used to analyze total
embryo body area in order to 1) reliably identify treatment-related effects and 2) focus
our analyses on targeted impacts on spontaneous activity in the absence of significant
effects on embryonic growth. Treatments resulting in a significant decrease in total body
area were not analyzed for spontaneous activity. Embryos exhibiting notochord
malformations that were not detected by analysis of total body area were also excluded
from analysis of spontaneous activity. Additional information about parameters used in
EthoVision XT 9.0 is provided in Table A.3. Additional details about the data extraction
and analysis process are provided in Figure A.2.

2.2.4 STATISTICAL ANALYSIS
All statistical procedures were performed using SPSS Statistics 20.0 (Chicago,
IL). Non-parametric tests were used for analyzing spontaneous activity data, as these data
were categorical and did not meet normality assumptions. A Kruskal-Wallis test was used
(α = 0.05) to test for main effect of treatment, and Mann-Whitney pair-wise comparisons
were used to test for differences between vehicle control columns 1 and 23 and treatment
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columns relative to vehicle control columns (α = 0.05). For chemical screening assays,
treatments were only considered significant if different from both control columns. For
total body area analysis, a general linear model (GLM) analysis of variance (ANOVA) (α
= 0.05) was used, as these data did not meet the equal variance assumption for non-GLM
ANOVAs. Pair-wise Tukey-based multiple comparisons of least square means were
performed to identify significant treatment-related effects. To estimate the median lethal
concentration (LC50) after static exposure to each chemical from 5 to 25 hpf, a fourparameter concentration-response curve was fit to percent mortality data using logtransformed chemical concentrations within Prism 6.0 (GraphPad Software Inc., La Jolla,
CA).

2.3 RESULTS
2.3.1 HCS ASSAY VARIABILITY
To determine assay variability, we imaged three independent control plates
containing embryos incubated in EM at 28ºC from 5-24 hpf, and then acclimated for 1
hour at 25ºC prior to imaging. Parameters provided in Figure A.2 and Tables A.2 and A.3
were used to analyze total body area and spontaneous activity for each control plate.
Percent survival and image success rates for each plate were consistently above 95% and
99.5%, respectively (Table 1 and Figure 2.2A). When summarized by column, survival
ranged from 87.5-100%, while image success rates ranged from 93.3-100% (Table A.4).
While total body area was consistent within and across control plates (Figure 2.2B),
spontaneous activity within and across control plates was variable, with an average
percent by column ranging from 36.3-63.4% across all three plates (Figure 2.2C).
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Based on performance within control plates, we then developed decision criteria
for assay success (Figure 2.3). The percent of embryos with spontaneous activity per
column ranged from 18.75% to 75% across all three plates (36 columns total), with the
majority of columns ranging from 25 to 74% (Figure A.4). Therefore, based on these
data, we concluded that spontaneous activity within each control group (columns 1 and
23 for chemical screening assays) must be >18% in order to be considered a successful
plate (Figure 2.3). Additionally, spontaneous activity within columns 1 and 23 must not
be significantly different (p>0.05) from each other based on a Mann-Whitney test. If both
criteria were met, the entire plate was then analyzed for total body area and spontaneous
activity (Figure 2.3).

3.3.2 HCS ASSAY REPRODUCIBILITY
Based on previously published data, nicotine and paraoxon were selected as
reference chemicals to evaluate assay reproducibility (Thomas et al., 2009; Yozzo et al.,
2013). Nicotine exposure resulted in no effect on survival, total body area, or
spontaneous activity (Figure A.5). However, in the absence of an effect on survival and
total body area at all concentrations tested, paraoxon exposure resulted in a
concentration-dependent decrease in the percent of embryos with spontaneous activity at
12.5, 25, and 50 µM (Figure 2.4). Based on this concentration-response test, three
reference plates containing 96 initial embryos per treatment were then exposed to vehicle
or 25 µM paraoxon. Percent survival, total body area, and image success rates of
paraoxon-treated embryos were similar to vehicle controls (Figure 2.5 and Table 2), and
the hypoactive effect of paraoxon on spontaneous activity was reproducible within and
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across all three reference plates (Figure 2.5). Based on results of control and reference
chemical plates, we concluded that this assay is reproducible based on sample sizes of 16
initial embryos per column.

3.3.3 CHEMICAL SCREENING
Following assay development and optimization, we tested a small chemical
library to evaluate the potential utility of this HCS assay for screening and prioritizing
chemicals for DNT testing. Based on data available from previous teratogenesis screens
using zebrafish embryos (Padilla et al., 2012), acute toxicity benchmarks (AC50) for
chemicals within the U.S. Environmental Protection Agency’s (EPA’s) ToxCast™
Phase-I chemical library were ranked from most to least potent based on survival and
gross malformations present at 6 dpf following a 8-hpf to 5-dpf exposure.

Using

protocols described in Figure A.2, the most potent 18 chemicals (Table A.1, excluding
nicotine and paraoxon) were selected to evaluate the ability of this assay to detect
targeted effects on spontaneous tail contractions. Two chemicals (tefluthrin and
milbemectin) were not commercially available (as of August 2013), and fentin was
insoluble in DMSO at concentrations as low as 2.5 mM. Therefore, these three chemicals
were not included in the final screen, resulting in a total of 15 chemicals tested in
concentration-response format.
A summary of statistical results and overall effects on spontaneous activity for all
chemicals screened is provided within Table A.5. Of the chemicals tested, rotenone was
the most acutely toxic based on survival and total body area, as 0.09 µM was the highest
concentration analyzed due to a significant decrease in total body area at 0.19 µM and
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0% survival in all other concentrations (Figure A.6). On the contrary, butafenacil,
flumetralin, propargite, tribufos, and pyraflufen-ethyl showed no evidence of acute
toxicity in this assay, with no effect on survival or total body area across all
concentrations tested (0.09-50 µM) (Figures A.9, A.11, A. 13, A.16, A.19).
Approximately one-third of the chemicals screened (thiram, fluthiacet-methyl,
pyraclostrobin, (Z,E)-fenpyroximate, and trifloxystrobin) resulted in steep concentrationresponse curves based on survival, where only a two-fold increase in concentration was
required to decrease survival from >85% to 0% (Figures A.7, A.12, A.14, A.15, A.20).
To determine the potential for DNT, spontaneous activity was assessed within
treatment groups with >85% survival and no significant decrease in mean total body area
relative to vehicle controls. Based on our chemical screen, we then compared the
maximum tolerated concentration (MTC) for body area and spontaneous activity (Figure
2.6). Out of all 15 chemicals screened, exposure to abamectin – a widely used insecticide
and chloride channel activator belonging to the avermectin class – resulted in a
significant decrease in spontaneous activity at concentrations as low as 3.125 µM (Figure
2.7). Based on these data, the entire ToxCast™ Phase-I chemical library was then
searched for other commercially available avermectins to determine whether exposure to
chemicals within the same class resulted in similar adverse effects on spontaneous
activity. Based on this search, emamectin benzoate was screened, and, similar to
abamectin, significantly decreased the percent of embryos with spontaneous activity (at
25 and 50 µM) in the absence of effects on gross embryonic development, albeit with
approximately 8-fold less potency than abamectin (Figure 2.8).
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2.4 DISCUSSION
Although assays quantifying zebrafish locomotion have been developed, the HCS
assay reported here provides a simpler discovery platform for identifying potential
developmental neurotoxicants. Using 384-well plates, we were able to 1) increase sample
size to 16 individual embryos per treatment (192 embryos total), 2) examine a broad
concentration-response (vehicle control and 10 chemical concentrations), 3) decrease
assay duration and volume of test material, and 4) identify chemicals that target the
developing nervous system at non-teratogenic concentrations. After confirming assay
variability and reproducibility using control plates and reference chemicals known to
affect spontaneous activity, we then screened 16 chemicals within the U.S. EPA’s
ToxCast™ Phase-I chemical library and found that exposure to abamectin and emamectin
benzoate – both potent avermectins – abolished spontaneous activity in the absence of
effects on survival and total body area.
During embryonic development, spontaneous tail contractions occur due to
innervation of primary motoneuron axons into target axial muscles in a highly
stereotyped, error-free manner (Kimmel et al., 1995; Myers, 1986). This form of
locomotion is controlled by neural networks within the spinal cord, as neither brain
lesions nor isolation of the spinal cord from descending brain inputs affect this behavior
(Downes and Granato, 2006). Although spontaneous activity has been suggested to occur
in the absence of external cues such as touch (Brustein et al., 2003; Saint-Amant and
Drapeau, 1998), there is evidence that spontaneous activity may be affected by highintensity light stimuli (Kokel et al., 2010). Despite controlling for developmental stage,
temperature, and light conditions, we observed a high degree of natural variability in the
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percent of control embryos exhibiting spontaneous activity. We attempted to minimize
this variation by loading two embryos per well and extending the imaging duration per
embryo; however, these changes had no impact on minimizing variation of this
behavioral phenotype. Therefore, since parameters were tightly controlled within our
assay, the environmental or biological factors responsible for variation observed in our
assay are currently unclear.
Despite the natural variation in control spontaneous activity, our assay detected a
significant decrease in spontaneous activity after exposure to paraoxon, and we
demonstrated that this effect was reproducible across reference plates. However, contrary
to previous studies in zebrafish (Thomas et al., 2009), nicotine did not affect spontaneous
activity, a discrepancy that was likely due to differences in experimental design and
exposure duration. In a study conducted by Thomas et al (2009), chorionated zebrafish
embryos were incubated from fertilization to 23 hpf in 50-mm petri dishes and placed in
groups of three embryos per dish. Embryos were then transferred to 30 µM nicotine for
five minutes, and an increase in the number of spontaneous tail contractions was
observed over this five-minute imaging period under transmitted light. In our assay,
chorionated embryos were individually exposed to treatment solution from 5 to 25 hpf
within single wells of a 384-well plate, and then imaged for six seconds each under
fluorescence. Therefore, the absence of a nicotine-induced effect on spontaneous activity
within our assay may be a result of different rearing conditions, extended exposure
duration, decreased image acquisition duration, and/or the use of fluorescence rather than
transmitted light.
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Out of 16 ToxCast™ Phase-I chemicals screened, exposure to 14 of these
chemicals resulted in no impact on spontaneous activity using this assay. Out of these 14
chemicals, five chemicals had no impact on survival, total body area, or spontaneous
activity up to 50 µM (the highest concentration tested), suggesting that these chemicals
exhibited limited embryonic uptake – due to high rates of chemical absorption to
microplate wells or low rates of chemical transport across the chorion – and/or negligible
toxicity during this stage of development. However, exposure to nine out of these 14
chemicals resulted in significant effects on survival or total body area at one or more
concentrations yet did not affect spontaneous activity at non-teratogenic concentrations,
suggesting that the primitive nervous system during this stage of development was not a
target organ for these nine chemicals.
Using this HCS assay, we discovered that exposure to abamectin and emamectin
benzoate – both potent avermectins – significantly decreased spontaneous activity in the
absence of effects on survival and total body area. Avermectins are primarily used for
control of insects and helminthes (Taylor, 2001) and are thought to induce neurotoxicity
by activation of either glutamate- or gamma aminobutyric acid (GABA)-gated chloride
channels, interfering with signal transmission between nerve cells (Bloomquist, 1996; US
Environmental Protection Agency, 2004). Although registered in the U.S. since the 1980s
(US Environmental Protection Agency, 2004), to our knowledge very few studies have
examined the neurotoxic effects of avermectin exposure on mammalian cells and model
organisms, particularly during early development. In mouse neuroblastoma N2a cells,
exposure to abamectin and doramectin resulted in a significant concentration-dependent
inhibition of neurite growth (Sun et al., 2010). In zebrafish, semi-static exposure to
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abamectin resulted in a decrease in swimming ability at 96-hpf (Tisler and Erzen, 2006).
Most importantly, within a DNT study similar to OECD Test Guideline 426
(Organization for Economic Co-operation and Development, 2007), exposure of mated
female Sprague-Dawley rats to emamectin benzoate from gestation day 6 through
lactation day 20 resulted in a dose-dependent decrease in motor activity in male and
female offspring on postnatal day (PND) 17 but not PND 21; this decrease was also
observed on PND 59 in females only (Wise et al., 1997). Therefore, based on our results
and limited data available within the published literature, exposure to avermectins
appears to result in disruption of nervous system function during early development.
In summary, this HCS assay provides a streamlined platform with sufficient
replication and exposure concentrations to screen and identify potential developmental
neurotoxicants. Given that we relied on an embryonic stage (25 hpf) with a less
developed nervous system compared to later larval stages (6-7 dpf), we recognize that our
assay has the potential to be biased toward identifying chemicals with specific neurotoxic
modes-of-action. However, compared to existing zebrafish-based locomotion assays
conducted within 96-well plates (Padilla et al., 2011), this assay provides shorter
exposure duration (1 day vs. 6 days) and decreased treatment solution volumes needed
for screening (50 µL vs. 250 µL per well for static exposures). As a result, within a tiered
testing framework, this assay has the potential for rapid, cost-effective prioritization of
chemicals for DNT assays that rely on later stages of zebrafish and rodent development.
Moreover, in the future this HCS assay can be readily coupled with reverse genetics
approaches to identify the potential role of aberrant neurotransmitter signaling in
chemically-induced effects on early neurodevelopment within zebrafish embryos. Over
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the long-term, we envision that this HCS assay will help uncover mechanisms of DNT
for pesticides and understudied high-production volume chemicals in commerce.
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Table 2.1: Image success rates for analysis of spontaneous activity and total body area
within control 25-hpf zebrafish embryos across three independent plates containing an
initial sample size of 192 embryos per plate. The percentage of live embryos was relative
to an initial sample size of 192 embryos per plate, whereas the percentage of analyzed
embryos was relative to the number of live embryos.

Control
Plate
1
2
3

Live Embryos
Total
Total
(#)
(%)
192
100.0
185
96.4
192
100.0

Spontaneous Activity
Analyzed
Analyzed
(#)
(%)
192
100.0
185
100.0
191
99.5
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Total Body Area
Analyzed
Analyzed
(#)
(%)
192
100.0
184
99.5
191
99.5

Table 2.2: Image success rates for analysis of spontaneous activity and total body area within reference chemical plates consisting of
25-hpf zebrafish exposed to vehicle or 25 µM paraoxon across three independent plates containing an initial sample size of 96
embryos per treatment per plate. The percentage of live embryos was relative to an initial sample size of 96 embryos per treatment per
plate, whereas the percentage of analyzed embryos was relative to the number of live embryos.

Plate #
1
2
3

Treatment
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Vehicle (0.1% DMSO)
25 µM Paraoxon
Vehicle (0.1% DMSO)
25 µM Paraoxon
Vehicle (0.1% DMSO)
25 µM Paraoxon

Live Embryos
Total
Total
(#)
(%)
93
96.9
93
96.9
95
99.0
93
96.9
95
99.0
95
99.0

Spontaneous Activity
Analyzed
Analyzed
(#)
(%)
93
100.0
93
100.0
95
100.0
93
100.0
95
100.0
95
100.0

Total Body Area
Analyzed
Analyzed
(#)
(%)
92
98.9
91
97.8
95
100.0
91
97.8
92
96.8
94
98.9

Figure 2.1: Diagram summarizing the exposure setup, image acquisition, and data
analysis endpoints for the HCS assay. Using automated image acquisition protocols and
parameters optimized for our ImageXpress® Micro Widefield High-Content Screening
System, each fli1:egfp embryo was imaged to assess the presence or absence of
spontaneous tail contractions.
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Figure 2.2: Survival (%) (A), total body area (µm2) (B), and spontaneous activity (%)
(C) across three independent control plates consisting of 192 initial embryos per plate.
Survival (%) and spontaneous activity (%) data are presented as mean ± SD across three
independent plates. Total body area data are presented as mean ± SD across all embryos
analyzed. N = final number of embryos analyzed. Numbers above each bar denote
percent spontaneous activity within that column.
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37
Figure 2.3: Decision tree for evaluation of assay success during exposure setup (Day 0), image acquisition (Day 1), and data
extraction/analysis (Day 1). Criteria for control survival (>85% survival) and spontaneous activity were developed to (1) reliably
identify treatment-related effects and (2) focus our analyses on targeted impacts on spontaneous activity in the absence of significant
effects on embryonic growth.

Figure 2.4: Paraoxon exposure results in a concentration dependent effect on
spontaneous activity in the absence of effects on survival and total body area. Total body
area data within each column are presented as mean ± SD. N = final number of embryos
analyzed per column. Numbers above each bar denote percent spontaneous activity
within that column. Asterisk denotes significant difference in percent spontaneous
activity from both vehicle controls (p<0.05). LC50 > 50 µM.
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Figure 2.5: Survival (%) (A), total body area (µm2) (B), and spontaneous activity (%)
(C) following exposure to vehicle (0.1% DMSO) or 25 µM paraoxon from 5 to 25 hpf in
a 384-well plate containing 96 initial embryos per treatment per plate. Survival (%) and
spontaneous activity (%) data are presented as mean ± SD across three independent
plates. Total body area data are presented as mean ± SD across all embryos analyzed. N =
final number of embryos analyzed across all three plates. Numbers above each bar denote
percent spontaneous activity within that column. Asterisk denotes significant difference
from both vehicle control columns 1 and 23 (p<0.05).
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Figure 2.6: Comparison of the maximum tolerated concentration (MTC) for body area
and spontaneous activity for 15 of the most acutely toxic ToxCast™ Phase-I chemicals
screened using the HCS assay. Numbers above points denote the number of chemicals
each point represents.
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Figure 2.7: Abamectin exposure results in a concentration dependent effect on
spontaneous activity in the absence of effects on survival and total body area. Total body
area data within each column are presented as mean ± SD. N = final number of embryos
analyzed per column. Numbers above each bar denote percent spontaneous activity
within that column. Asterisk denotes significant difference in percent spontaneous
activity from both vehicle controls (p<0.05). LC50 > 50 µM.
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Figure 2.8: Emamectin benzoate exposure resulted in a concentration dependent effect
on spontaneous activity in the absence of effects on survival and total body area. Total
body area data within each column are presented as mean ± SD. N = final number of
embryos analyzed per column. Numbers above each bar denote percent spontaneous
activity within that column. Asterisk denotes significant difference in percent
spontaneous activity from both vehicle controls (p<0.05). LC50 >50 µM.
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CHAPTER 3
ABAMECTIN INDUCES RAPID AND REVERSIBLE HYPOACTIVITY WITHIN EARLY
ZEBRAFISH EMBRYOS
3.1 INTRODUCTION
Avermectins are naturally occurring 16-membered macrocyclic lactones produced
as fermentation products by a soil-dwelling actinomycete bacterium (Streptomyces
avermitilis) (Rugg, 2010). Isolated in the 1970s from a soil sample collected within
Japan, these compounds have potent antihelminthic and antiparasitic properties (Rugg,
2010), with a unique ability to act as “endectocides” on both ecto- and endoparasites
(Omura and Crump, 2004). Although the mechanism of action is still not fully
understood, avermectins are thought to induce neurotoxicity within invertebrates and
vertebrates by direct activation or potentiation of glutamate- and/or γ-aminobutyric acid
(GABA)-gated chloride channels, resulting in paralysis and eventually death
(Bloomquist, 1996; Sanchez-Bayo, 2012). Despite uncertainties about the specific
mechanism of action, the broad-spectrum activity of avermectins has led to widespread
use for animal health and crop protection over the last 30 years.
Avermectins consist of four related compounds (A1, A2, B1, B2), each containing a
major (A1a, A2a, B1a, B2a) and minor (A1b, A2b, B1b, B2b) component (Clark et al., 1995;
Jansson et al., 1996). As a synthetic derivative of avermectin B1 (or abamectin),
ivermectin was the first commercially available avermectin introduced in 1981 as an
antiparasitic in domestic animals. In addition to veterinary applications, ivermectin is also
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used to treat onchocerciasis in humans, a disease commonly known as River Blindness
(Campbell, 2012). In 1985, abamectin (80% B1a:20% B1b) was introduced as an
agricultural insecticide and miticide in addition to use as a veterinary antiparasitic drug.
As a result, abamectin is now registered worldwide for insect and mite control on crops
such as citrus, nuts, ornamental plants, cotton, vegetables, strawberries, and grapes, as
well as for control of fire ants (Dybas, 1989). From 1992 to 2005, only about 10,000
pounds of abamectin per year were used in the United States (US), with the majority of
use on orchards (almonds and oranges) and/or grapes within California, Florida, and
Washington. However, following registration of abamectin as a seed treatment to control
parasitic nematodes on cotton in 2006, use expanded throughout the Southeastern United
States and into Texas, increasing to approximately 40,000-50,000 pounds per year from
2006-2009 (US Environmental Protection Agency, 2005; US Geological Survey, 2011).
By 2011, the use of abamectin nearly doubled to approximately 100,000 pounds per year
due to increased penetration of the cotton market and approval as a nematicide seed
treatment on corn throughout the US (US Environmental Protection Agency, 2011; US
Geological Survey, 2011).
Abamectin is highly lipophilic, adsorbs strongly to soil surfaces, and undergoes
rapid photolysis, all of which limit the mobility and transport of abamectin from treated
agricultural fields into surface water and groundwater (Wislocki et al., 1989). To our
knowledge, abamectin concentrations have not been monitored within dietary (food and
drinking water) sources of human exposure, likely because of very low foliar application
rates (<0.025 lb active ingredient/acre) as well as minimal transport and persistence in the
environment. Based on exposure estimates using the Dietary Exposure Evaluation Model
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(DEEM), the US Environmental Protection Agency (EPA) recently concluded that, for
the general US population, dietary (food and drinking water) exposures to abamectin are
below the level of concern for acute and chronic risk using rat-based no-observable
adverse effect levels (NOAELs) derived from acute (adult) neurotoxicity (NOAEL = 0.5
mg/kg/day) and developmental neurotoxicity (NOAEL = 0.12 mg/kg/day) studies,
respectively (US Environmental Protection Agency, 2013). Interestingly, although adult
behavior was the most sensitive endpoint affected within both acute and sub-chronic
neurotoxicity studies, pup body weight – rather than pup behavior – during post-natal
development was the most sensitive endpoint affected within the developmental
neurotoxicity study (US Environmental Protection Agency, 2013). Therefore, as prenatal
development is not monitored and pups are not directly dosed within a developmental
neurotoxicity study, these data suggest that the neurotoxic effects of abamectin in utero
(if any) may be reversible following delivery. However, to our knowledge no studies
have investigated the potential for abamectin-induced neurotoxicity during vertebrate
embryonic development and whether these effects (if any) are reversible following
elimination of abamectin exposure.
Based on a high-content screen conducted within Chapter 2, we demonstrated that
exposure of zebrafish embryos to abamectin from 5-25 hours post-fertilization (hpf)
abolished spontaneous activity – an indicator of developmental neurotoxicity – in the
absence of effects on survival and gross morphology. Therefore, as zebrafish is a wellestablished model for early vertebrate neurodevelopment (Eisen et al., 1989; Westerfield
et al., 1990), the overall objective of this study was to begin investigating the mechanism
of abamectin-induced hypoactivity. To accomplish this objective, we conducted
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experiments to (1) identify developmental stages susceptible to abamectin exposure
within the first 24 h of embryogenesis (which is roughly equivalent to the first 16 days of
prenatal rat development); (2) determine whether abamectin-induced effects on
spontaneous activity are reversible; and (3) identify potential molecular initiating events
responsible for abamectin-induced hypoactivity.

3.2 MATERIALS AND METHODS
3.2.1 ANIMALS
Adult fli1:egfp or wildtype (5D) zebrafish were raised and maintained on a 14hour:10-hour light:dark cycle within an Aquatic Habitats Five-Shelf Stand-Alone
recirculating system containing photoperiod enclosures and conditioned reverse osmosis
(RO) water (~27-28°C). Adult females and males were bred directly on-system using intank breeding traps suspended within 3 L tanks. For all experiments described below,
newly fertilized eggs were staged according to previously described methods (Kimmel et
al., 1995). All fish were handled and treated in accordance with approved Institutional
Animal Care and Use Committee (IACUC) protocols at the University of South Carolina
– Columbia.

3.2.2 CHEMICALS
Abamectin, fipronil, and endosulfan were purchased from ChemService, Inc.
(West Chester, PA). Stock solutions of each chemical were prepared by dissolving
chemicals in high performance liquid chromatography (HPLC)-grade dimethyl sulfoxide
(DMSO) (50 mM), and then performing two-fold serial dilutions into DMSO to create

46

stock solutions for each working solution. All stock solutions were stored at room
temperature within 2 mL amber glass vials containing polytetrafluoroethylene (PTFE)lined caps. For each individual exposure, working solutions of all treatments were freshly
prepared by spiking stock solutions into embryo media (EM) (5 mM NaCl, 0.17 mM
KCl, 0.33 mM CaCl2, 0.33 mM MgSO4), resulting in 0.1% DMSO within all vehicle
control and treatment groups.

3.2.3 EMBRYONIC ABAMECTIN EXPOSURES
Newly fertilized eggs were collected immediately after spawning and placed in
groups of approximately 100 per petri dish within a light- and temperature-controlled
incubator until 5 hpf. Prior to each experiment, 50 mL glass beakers were thoroughly
rinsed with DMSO and RO water. For initial screening assays, viable fli1:egfp embryos
were exposed to vehicle (0.1% DMSO) or abamectin (0.0625-0.5 µM) in triplicate glass
beakers (20 per replicate beaker) under static conditions at 28°C from 5 to 24 hpf. At 24
hpf, all beakers were removed from the incubator and allowed to acclimate at 25°C
within treatment solution for 1 hour before imaging. At 25 hpf, all embryos within each
treatment beaker were videoed for 10 seconds under transmitted light using an Olympus
MVX10 MacroView stereomicroscope equipped with an Olympus DP72 Digital Color
Camera and Olympus DP2-BSW Imaging Software. Videos were analyzed manually to
assess percent spontaneous activity within each beaker. Inactive embryos were defined as
embryos that were immobile during the entire 10-second video (152 frames), and were
assigned an activity value of 0. Embryos that moved for at least one out of 152 frames

47

were considered active and assigned an activity value of 1. Based on these values, percent
spontaneous activity was then calculated for each beaker.
To identify developmental windows susceptible to abamectin exposure within the
first 24 h of zebrafish embryogenesis, fli1:egfp embryos were exposed to vehicle (0.1%
DMSO) or 0.5 µM abamectin in triplicate glass beakers (20 per replicate beaker) using
the following static exposure scenarios: (1) 5-25 hpf; (2) 10-25 hpf; and (3) 23-25 hpf.
After beakers were removed from the incubator, embryos were acclimated at 25°C within
treatment solution from 24-25 hpf prior to video recording under transmitted light, and
spontaneous activity was analyzed as described above. To determine whether abamectininduced effects on spontaneous activity were reversible, fli1:egfp embryos were first
placed in triplicate glass beakers (20 per replicate beaker) containing EM only at 28°C
from 5-23 hpf. Embryos were then exposed to vehicle (0.1% DMSO) or 0.5 µM
abamectin from 23-27 hpf at room temperature, rinsed twice, and maintained in clean
glass beakers containing clean EM only at room temperature until 31 hpf. Although
previous studies have concluded that spontaneous activity occurs between approximately
19 and 29 hpf (Saint-Amant and Drapeau, 1998), we have found that, at 28°C, activity
within vehicle control embryos continues beyond 31 hpf, enabling the measurement of
activity for a 4-hour recovery period. A “baseline” video was recorded for each beaker
before treatment solutions were added, and subsequent videos were recorded every 15
minutes under transmitted light. Although we did not use a FITC filter cube for imaging,
we used fli1:egfp embryos to be consistent with our study in Chapter 2 and, while not
expected, eliminate any potential for strain-specific variation in the timing and frequency
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of spontaneous activity. Percent spontaneous activity was then determined for each
beaker at each time point as described above.

3.2.4 IN

SITU ASSESSMENT OF PRIMARY MOTONEURON MORPHOLOGY WITHIN

25-HPF

ZEBRAFISH EMBRYOS

Wildtype (5D) embryos were exposed in triplicate glass beakers to either vehicle
(0.1% DMSO) or 0.5 µM abamectin from 5-25 hpf at 28°C. Live embryos were then
dechorionated by incubating embryos in 0.5 mg/mL pronase for 20 minutes on a shaker
at 100 rpm. Embryos were then washed in RO water and fixed overnight in 4%
paraformaldehyde. Fixed embryos were permeabilized by incubating in cold acetone at
-20°C for 15 minutes, and then rinsed four times in phosphate-buffered saline
(PBS)/0.1% Tween-20 (PBST) for 5 minutes per wash. Permeabilized embryos were
incubated in fresh blocking buffer (PBST/2% sheep serum/2 mg/mL bovine serum
albumin) for 4 hours at room temperature with gentle agitation, and then incubated
overnight at 4°C with gentle agitation in blocking buffer containing a 1:20 dilution of
znp-1 IgG2a supernatant (DSHB, University of Iowa). znp-1 IgG2a is a zebrafish-specific
antibody that recognizes cell bodies and axons of primary motoneurons in 25-hpf
zebrafish (Pike et al., 1992; Trevarrow et al., 1990). Following primary antibody
incubation, embryos were washed five times with gentle agitation in PBST at room
temperature for 15 minutes each. Embryos were incubated overnight at 4°C with gentle
agitation in blocking buffer containing a 1:500 dilution of Alexa Fluor 488 (AF488)conjugated goat anti-mouse IgG2a (Invitrogen) to visualize znp-1 localization in situ.
Finally, secondary antibody-labeled embryos were washed five times with gentle
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agitation in PBST at room temperature for 15 minutes each, and then stored in PBS at
4°C until imaging. Labeled embryos were imaged at 10X magnification using a FITC
filter cube and Olympus BX51 Research System Microscope equipped with an Olympus
DP72 Digital Color Camera and Olympus DP2-BSW Imaging Software.

3.2.5 EMBRYONIC EXPOSURES WITH GABA RECEPTOR ANTAGONISTS
We used fipronil and endosulfan – two insecticides that antagonize the GABA
receptor – to test whether abamectin-induced hypoactivity was mediated through the
GABA receptor. To identify the maximum tolerated concentration that did not adversely
impact spontaneous activity, range-finding exposures for fipronil (3.125-25 µM) and
endosulfan (0.625-5 µM) alone were first conducted under static exposure conditions in
50 mL beakers as described above. Based on these range-finding exposures, the final noeffect concentration used for these experiments was 12.5 µM and 1.25 µM for fipronil
and endosulfan, respectively. First, three replicate beakers of fli1:egfp embryos (20 per
replicate beaker) were pretreated with vehicle (0.1% DMSO), 12.5 µM fipronil, or 1.25
µM endosulfan from 5-23 hpf at 28°C. Embryos were then washed twice with clean EM
and exposed to vehicle (0.1% DMSO) or 0.5 µM abamectin in clean beakers from 23-25
hpf. After a 1 hour acclimation from 24-25 hpf, videos were recorded and spontaneous
activity was analyzed as described above.

3.2.6 TOTAL RNA ISOLATION AND REAL-TIME PCR
Four replicate pools of 5-, 10-, and 23-hpf zebrafish embryos (100 individuals per
pool) incubated in clean EM at 28°C were snap-frozen in liquid nitrogen and stored at -
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80°C. Following homogenization of embryos using a PowerGen Homogenizer (Fisher
Scientific), an SV Total RNA Isolation System (Promega) was used to extract total RNA
from pooled embryos. Prior to sample elution, total RNA samples were on-columndigested with DNase-I to remove any DNA contamination. Total RNA concentrations
and 260/280 ratios were determined using a Nano Drop ND-2000 spectrophotometer and
samples were stored at -80°C.
Per manufacturer’s instructions, first-strand cDNAs were generated from total
RNA samples using oligo (dT)15 primers and AMV Reverse Transcriptase (Promega); all
cDNA samples were stored at -20°C until use. gabra1, gabrb2, gabrg2, and 18s rRNA
cDNAs were amplified using the following primers: gabra1, forward primer 5’GTCTGTTACGCCTTTGTCTTCT-3’,

reverse

primer

5’-GCGGTGTAGG

TGTTGTTCTT -3’; gabrb2, forward primer 5’-GTGGCGGTAGGGATGAATATAG-3’,
reverse primer 5’-ACGCGGTTATCCAAGGTTAG-3’; gabrg2, forward primer 5’TACGGAACGCTACACTACTTTG-3’, reverse primer 5’-CCAGACATTCGTAGCC
GTATT -3’; and 18s rRNA, forward primer 5’-TCGCTAGTTGGCATCGTTTATG-3’,
reverse primer 5‘CGGAGGTTCGAAGACGATCA-3’. As 18s rRNA is stably expressed
throughout zebrafish embryogenesis (McCurley and Callard, 2008), this gene was
selected as an internal control for each developmental stage. Per manufacturer’s
instructions, approximately 75 ng of cDNA for each target was PCR amplified using
GoTaq qPCR Master Mix (Promega) and an Applied Biosystems 7900HT Fast RealTime PCR System. Real-time PCR reaction conditions were 2 minutes at 95°C followed
by 45 cycles of 95°C for 30 seconds, 50°C for 30 seconds, and 72°C for 15 seconds.
Relative quantitation of gene expression within each reaction was calculated using the
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comparative cycle threshold (Ct) method as previously described (Jayasinghe and Volz,
2012).

3.2.7 PHYLOGENETIC ANALYSIS
Gene and protein databases available within the National Center for
Biotechnology Information (NCBI) were searched to find protein sequences for all
zebrafish ionotropic GABA receptor (also known as GABAAR) subunits. If protein
sequences submitted to NCBI were not available, we relied on protein sequences
predicted

from

the

most

current

assembly

of

the

zebrafish

genome

Zv9

(http://www.ncbi.nlm.nih.gov/genome?term=danio%20rerio). Due to minor differences
in NCBI’s nomenclature for GABA receptor α4 subunit, the Basic Local Alignment
Search Tool (BLAST) was used to find the zebrafish homolog for the human GABA
receptor α4 subunit. For each zebrafish GABA receptor subunit, BLAST Link (BLink)
was used to obtain the most similar protein sequence within rat (Rattus norvegicus),
mouse (Mus musculus), and human (Homo sapiens). Multiple alignment of all protein
sequences

(61

total)

was

conducted

using

EMBL-EBI’s

Clustal

Omega

(http://www.ebi.ac.uk/Tools/msa/clustalo/), and alignment results were imported into
EMBL-EBI’s

ClustalW2

Phylogeny

to

generate

a

phylogenetic

tree

(http://www.ebi.ac.uk/Tools/phylogeny/clustalw2_phylogeny/).

3.2.8 STATISTICAL ANALYSES
All statistical procedures were performed using SPSS Statistics 21.0 (Chicago,
IL). For analysis of all percent spontaneous activity data, a general linear model (GLM)
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analysis of variance (ANOVA) (α = 0.05) was used, as these data did not meet the equal
variance assumption for non-GLM ANOVAs. For analysis of real-time PCR data, a GLM
ANOVA (α = 0.05) was used to compare Ct values for gabra1 across all three
developmental stages. Pair-wise Tukey-based multiple comparisons of least square means
were performed to identify significant stage- or treatment-related effects.

3.3 RESULTS
3.3.1 ABAMECTIN ABOLISHES SPONTANEOUS ACTIVITY WITHIN EARLY ZEBRAFISH EMBRYOS
Using a 384-well-based high-content screening assay, we demonstrated in
Chapter 2 that exposure of developing zebrafish embryos to ≥3.125 µM abamectin – an
avermectin insecticide – from 5-25 hpf abolished spontaneous activity in the absence of
effects on survival and gross morphology. Due to shifting our focus away from screening
as well as logistical challenges associated with aspirating treatment solution from 384well plates, we completed all follow-up experiments within glass beakers. For this study,
we first exposed embryos to abamectin within 50 mL glass beakers to identify the
nominal concentration that completely eliminated spontaneous activity, as we expected
this concentration to be less than the concentration within glass-bottom 384-well plates
due to greater sorption of abamectin to plastic well walls. Similar to 384-well plates,
static exposure of 5-hpf zebrafish embryos to abamectin in glass beakers resulted in a
concentration-dependent decrease in percent spontaneous activity at 25 hpf in the absence
of effects on survival (≥85% average survival across all concentrations tested) (Figure
3.1). However, complete elimination of spontaneous activity was observed at 0.5 µM
abamectin – a nominal concentration approximately ~6-fold lower than the concentration
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required to eliminate spontaneous activity within 384-well plates. Therefore, as exposure
to 0.5 µM abamectin did not result in gross abnormalities, we relied on this exposure
concentration for all subsequent experiments.

3.3.2 ABAMECTIN DOES NOT AFFECT NEURITE OUTGROWTH OF SPINAL MOTONEURONS
To determine whether exposure to abamectin from 5-25 hpf affected neurite
outgrowth within zebrafish embryos, we used whole-mount immunohistochemistry to
label the axons of primary motoneurons in situ. Similar to fli1:egfp embryos, exposure of
wildtype (5D) embryos to 0.5 µM abamectin eliminated spontaneous activity. Although
survival was ≥90% and all vehicle- and abamectin-exposed embryos developed normally,
abamectin exposure did not appear to impact neurite outgrowth of primary motoneurons
compared to vehicle-exposed embryos (Figure 3.2), suggesting that abamectin-induced
elimination of spontaneous activity was not associated with effects on primary
motoneuron development.

3.3.3 ABAMECTIN INDUCES RAPID EFFECTS ON SPONTANEOUS ACTIVITY
To identify developmental stages susceptible to abamectin-induced hypoactivity
within the first 25 hours of zebrafish embryogenesis, we initiated exposure of embryos to
vehicle or 0.5 µM abamectin at 5, 10, and 23 hpf and then evaluated spontaneous activity
at 25 hpf. Average survival across all exposure groups was ≥95% (Figure 3.3A), and
average spontaneous activity within vehicle-exposed embryos was 83% (Figure 3.3B).
Surprisingly, similar to exposures initiated at 5 hpf, developing zebrafish embryos were
equally susceptible to abamectin-induced hypoactivity when exposures were initiated at
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10 and 23 hpf (Figure 3.3B). Given that a 2-hour exposure resulted in nearly identical
effects as a 20-hour exposure, these data suggest that, rather than impacting
neurodevelopment, abamectin induced rapid neurophysiological effects within early
zebrafish embryos.

3.3.4 ABAMECTIN-INDUCED

HYPOACTIVITY IS REVERSIBLE FOLLOWING TRANSFER TO

CLEAN EMBRYO MEDIA

As the effects of abamectin on spontaneous activity were rapid, we then
determined whether abamectin-induced effects on spontaneous activity were reversible.
Embryos were exposed to vehicle or 0.5 µM abamectin from 23-27 hpf, and then
transferred to clean EM until 31 hpf. Baseline (pretreatment) spontaneous activity for
embryos within beakers labeled for vehicle or abamectin exposure was 86.7 and 87.5%,
respectively (Figure 3.4). During the 4-hour exposure period, spontaneous activity within
vehicle-exposed embryos remained relatively stable and ranged from 82 to 97% (Figure
3.4). Although activity within vehicle-exposed embryos started to decline toward the end
of the 4-h recovery period, there were no significant differences in spontaneous activity at
all time points compared to within-vehicle baseline activity. On the contrary, addition of
abamectin resulted in a rapid decline in spontaneous activity from 23-27 hpf (Figure 3.4).
Compared to within-treatment baseline activity, a significant decrease in percent
spontaneous activity was observed at 24.75 hpf – only 1.75 hours after initiation of
abamectin exposure – and spontaneous activity continued to decline, reaching as low as
7.5% by the end of the 4-hour exposure period (Figure 3.4). However, transfer of
abamectin-exposed embryos to clean EM resulted in a rapid increase in spontaneous
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activity from 27-31 hpf, with complete recovery observed by 30.25 hpf – approximately
3.25 h after immersion within clean EM.

3.3.5 ABAMECTIN-INDUCED

HYPOACTIVITY IS BLOCKED BY PRETREATMENT WITH

GABA

ANTAGONISTS

To test the hypothesis that abamectin-induced hypoactivity within zebrafish
embryos was mediated through reversible activation of GABA-gated chloride channels,
we pretreated zebrafish embryos to vehicle or non-toxic concentrations of fipronil or
endosulfan – two insecticides that antagonize the GABA receptor – from 5-23 hpf, and
then exposed embryos to vehicle or abamectin from 23-25 hpf. Based on initial rangefinding exposures with fipronil and endosulfan, average embryo survival across all
exposure groups was ≥98% (Figure 3.5A and B), and a significant decrease in percent
spontaneous activity was observed at the highest concentration tested (Figure 3.5C and
D). Therefore, for pretreatment experiments with abamectin, we selected 12.5 µM
fipronil and 1.25 µM endosulfan as the maximum tolerated concentrations based on the
absence of effects on spontaneous activity (Figure 3.5C and D).
In pretreatment experiments with either fipronil or endosulfan, average survival
within all exposure groups was ≥90% (Figure 3.6A and B). Spontaneous activity within
vehicle controls was at least 74% and, in both cases, hypoactivity was observed within
abamectin-exposed embryos pretreated with vehicle (Figure 3.6C and D). However,
spontaneous activity within abamectin-exposed embryos pretreated with 12.5 µM fipronil
(Figure 3.6C) or 1.25 µM endosulfan (Figure 3.6D) ranged from 74 to 87% and was not
significantly different from vehicle-exposed embryos. Therefore, abamectin-induced
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hypoactivity was blocked by pretreatment with non-toxic concentrations of two GABA
receptor antagonists, suggesting that abamectin-induced hypoactivity may be mediated
through the GABA receptor.

3.3.6

GABRA1 AND GABRB2 ARE EXPRESSED DURING EARLY STAGES OF EMBRYONIC

DEVELOPMENT

As the α1, β2, and γ2 subunits are the most prevalent ionotropic GABA receptor
subunits within the rat brain (Dawson et al., 2000; Johnston, 1996; McKernan and
Whiting, 1996; Whiting, 2003), we measured the relative levels of gabra1, gabrb2, and
gabrg2 transcripts at 5, 10, and 23 hpf using real-time PCR to determine whether these
subunits were present during early development. Since gabrg2 transcripts were nondetectable at all three stages (data not shown), we focused our analysis on gabra1 and
gabrb2, both of which were detected at 5, 10, and 23 hpf. Relative to gabrb2, gabra1
transcripts were ~70-fold lower at 5 hpf but ~75- and ~17-fold higher at 10 and 23 hpf,
respectively (Figure 3.7). In addition, gabra1 transcript levels were significantly different
from one another across all three developmental stages (Figure 3.7).

3.3.7 IONOTROPIC GABA

RECEPTOR SUBUNITS WITHIN ZEBRAFISH AND MAMMALS ARE

HOMOLOGOUS

To determine whether protein sequences of zebrafish and mammalian ionotropic
GABA receptor subunits were similar, we constructed a phylogenetic tree to compare
GABA receptor subunits across four species: zebrafish, rat, mouse, and human. As
expected, phylogenetic analysis showed that, with the exception of zebrafish GABA
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receptor α6 and α4 subunits, the majority of GABA receptor subunits sharing the same
letter (i.e., γ, ρ, and β) clustered into distinct clades and, within each clade, rat, mouse,
and human subunits were more similar to each other relative to zebrafish (Figure 3.8).
Therefore, these data indicate that zebrafish and mammalian ionotropic GABA receptor
subunits are homologous, similarities that are likely due to highly conserved and
functionally important sequence domains (e.g., ligand-binding domain) within vertebrate
ionotropic GABA receptor subunits.

3.4 DISCUSSION
Using zebrafish as a model, the objective of this study was to begin investigating
the mechanism of abamectin-induced hypoactivity during embryonic development and
explore whether this effect was reversible following cessation of exposure. After
confirming that static exposure of embryos to 0.5 µM abamectin from 5-25 hpf in glass
beakers eliminated spontaneous activity, we demonstrated that (1) abamectin did not
affect neurite outgrowth from spinal motoneurons; (2) compared with exposure from 525 hpf, developing embryos were equally susceptible to abamectin-induced hypoactivity
when exposures were initiated at 10 and 23 hpf; and (3) abamectin-induced hypoactivity
was reversible after immersion of exposed embryos in clean water. Using fipronil and
endosulfan (insecticides that antagonize the GABA receptor) as pharmacologic tools, we
found that pretreatment of embryos with non-toxic concentrations of either antagonist
from 5-23 hpf, followed by exposure to abamectin from 23-25 hpf, resulted in
spontaneous activity levels similar to embryos exposed to vehicle alone. Finally, using
quantitative PCR and phylogenetic analysis, we then confirmed the presence of GABA
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receptor α1 and β2 subunits in zebrafish at 5, 10, and 23 hpf, and demonstrated that
zebrafish ionotropic GABA receptor subunits are homologous to mammalian ionotropic
GABA receptor subunits.
Due to the difficulty in assessing behavioral endpoints in utero, little is known
about the potential effects of abamectin exposure during vertebrate embryonic
development. Our results showed that, within abamectin-exposed embryos, elimination of
spontaneous activity occurred in the absence of effects on survival and neurite outgrowth
of spinal motoneurons. However, this effect on locomotion was rapid, as spontaneous
activity within zebrafish embryos decreased to nearly 7% after just 2 h of abamectin
exposure (23-25 hpf), suggesting that abamectin induces rapid, functional effects on the
nervous system rather than affecting motoneuron growth. Given that abamectin is
moderately hydrophobic (low Kow = 4.4), rapid abamectin transport across the chorion
into the embryo likely accounted for the rapid decrease in spontaneous activity observed
(US Environmental Protection Agency, 2010). Similarly, in a 14-d acute neurotoxicity
study within adult rats, the most sensitive endpoints affected after exposure to the highest
abamectin concentration (6.0 mg/kg/day) by oral gavage included tiptoe gait, reduced
splay reflex, and, most relevant to this study, decreased motor activity (US
Environmental Protection Agency, 2013). Despite rapid abamectin-induced hypoactivity
within 4 h of exposure, embryos quickly recovered 3.5 h following transfer to clean
water, suggesting that abamectin reversibly binds to ligand-gated chloride channels and
inhibits neurotransmission. Although spontaneous activity within vehicle-exposed
embryos slightly declined at the end of the recovery period, this was expected due to the
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narrow time window for this behavior during normal embryonic development (SaintAmant and Drapeau, 2000).
Interestingly, the sedative, anticonvulsant effects of abamectin observed in
zebrafish and rats are similar to effects produced in mice and humans following exposure
to benzodiazepines and other compounds that interact with the GABA receptor complex
(Dawson et al., 2000; Zanette et al., 2013). These types of compounds – including
barbiturates, benzodiazepines and ethanol – fall into a larger class of drugs known as
sedative-hypnotics, and are used to reduce tension and anxiety, relax muscles, and/or
induce sleep (Boles and Miotto, 2003). Therefore, spontaneous activity represents an
integrative behavioral readout that, combined with transparent, ex utero development of
zebrafish embryos, allows for control of exposure and recovery windows and, as such,
can be used to identify compounds with an abamectin-like mechanism of action.
Abamectin is thought to induce neurotoxicity in invertebrates and vertebrates by
activation of ligand-gated chloride channels, interfering with signal transmission between
nerve cells (Bloomquist, 1996). In vertebrates, although both GABA and glycine
receptors are selective for chloride, previous findings demonstrate that abamectininduced toxicity occurs primarily through activation of GABA-gated chloride channels
(Coccini et al., 1993; Dawson et al., 2000). We demonstrated that pretreatment of
embryos with non-toxic concentrations of fipronil and endosulfan – two insecticides that
antagonize the GABA receptor – blocked abamectin-induced hypoactivity. Although
higher concentrations of both antagonists resulted in decreased spontaneous activity, this
is consistent with the paralyzing effects of GABA receptor antagonists at toxic
concentrations due to prevention of chloride ion uptake, leading to an overstimulation of
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neurons (Connelly, 2001). Though fipronil has been shown to inhibit glycine receptor
isoforms (Islam and Lynch, 2012), GABA receptors have been implicated as the primary
target for both fipronil and endosulfan (Cole et al., 1993; Eldefrawi and Eldefrawi, 1987).
In addition, we recognize that these insecticides may have the potential to bind other
receptors within zebrafish embryos; however, initial attempts to pretreat embryos with
strychnine – a rodenticide that antagonizes the glycine receptor – failed to block the
hypoactive effects of abamectin (Figure B.3). The ability of fipronil (a phenylpyrazole
insecticide) and endosulfan (a cyclodiene insecticide) – two hydrophobic compounds
with distinct chemical structures – to prevent abamectin-induced hypoactivity suggests
that abamectin-induced inhibition of neurotransmission within 25-hpf zebrafish embryos
may be mediated through the GABA receptor.
At the time spontaneous tail contractions commence, three primary motoneurons
and seven interneurons are present within the zebrafish spinal cord (Brustein, 2003). As
the neurotransmitter GABA is not localized to primary motoneurons in 26-hpf zebrafish
(Tallafuss and Eisen, 2008), these findings relative to our data suggests that abamectin
may act within the central nervous system, blocking signal transmission from
interneurons to excitatory motoneurons (Campbell et al., 1983). While abamectin may
inhibit neurotransmission by direct binding to the GABA receptor or increasing
endogenous GABA concentrations (Novelli et al., 2012), there is evidence that the
GABA receptor β subunit is a key subunit for avermectin activity (Arena et al., 1993) and
that abamectin potentiates β1- and β2-containing GABA receptors (Dawson et al., 2000).
Our quantitative PCR data demonstrate that β2 and α1 GABA receptor subunits are
present within early-stage zebrafish embryos. Most importantly, these subunits are
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present at 23 hpf, the time point when addition of abamectin eliminates spontaneous
activity. Although we have not amplified additional GABA receptor subunits, some of
these subunits are likely present at 23 hpf. Although the presence of these subunits does
not confirm whether abamectin eliminates activity by interacting with the GABA
receptor, these data do indicate the potential for this interaction to occur. Moreover, our
phylogenetic analyses show that zebrafish and mammalian ionotropic GABA receptor
subunits are homologous, demonstrating that if abamectin is interacting with the GABA
receptor in zebrafish, this finding may have relevance to rodent models and humans.
In summary, this study resulted in three major findings: 1) abamectin-induced
hypoactivity within zebrafish embryos occurs within 2 h of exposure, an effect that is
reversed following transfer of abamectin-exposed embryos to clean water; 2) abamectininduced hypoactivity is blocked by pretreatment with non-toxic concentrations of fipronil
and endosulfan, two insecticides that antagonize the GABA receptor; and 3) GABA
receptor subunits present within the first 24 h of zebrafish embryogenesis are
homologous to mammalian GABA receptor subunits. While our data suggests that
abamectin-induced hypoactivity during embryonic development may not result in longterm locomotive effects, there may be a need to evaluate the potential long-term effects
of early abamectin exposure on cognition at later stages of development. Moreover, our
study supports the conclusion that spontaneous activity represents an integrative
behavioral readout that has the potential to detect GABA receptor agonists – and likely
other neuroactive chemicals – within a physiologically relevant, intact organism.
Therefore, within a tiered testing framework, early stages of embryonic zebrafish may be
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useful as a model for screening and prioritizing chemicals for developmental
neurotoxicity testing in mammalian models.

63

Figure 3.1: Abamectin exposure from 5-25 hpf results in a concentration-dependent
decrease in spontaneous activity in the absence of effects on survival, with complete
elimination of spontaneous activity observed at 0.5 µM abamectin. (A) Survival (mean ±
SD) and (B) spontaneous activity (mean ± SD) following exposure to vehicle (0.1%
DMSO) or 0.0625-0.5 µM abamectin. Numbers above each bar denote mean percent
spontaneous activity. Asterisk (*) denotes significant difference in percent spontaneous
activity from vehicle control (p<0.05). N = three replicate beakers per treatment and 20
initial embryos per replicate beaker.
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Figure 3.2: Abamectin does not affect gross primary motoneuron morphology of 25-hpf
zebrafish embryos. Fixed wildtype (5D) embryos exposed to vehicle (0.1% DMSO) or
abamectin (0.5 µM) from 5-25 hpf were incubated in znp-1 antibody overnight at 4°C
followed by an overnight incubation in goat anti-mouse IgG2a Alexa Fluor 488.
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Figure 3.3: Zebrafish embryos are susceptible to abamectin-induced hypoactivity
following initiation of exposure at 5, 10 or 23 hpf. (A) Survival (mean ± SD) and (B)
spontaneous activity (mean ± SD) following exposure to vehicle (0.1% DMSO) from 525 hpf or 0.5 µM abamectin from 5-25 hpf, 10-25 hpf, or 23-25 hpf. Numbers above each
bar denote mean percent spontaneous activity. Asterisk (*) denotes significant difference
in percent spontaneous activity from vehicle control (p<0.05). N = three replicate beakers
per treatment and 20 initial embryos per replicate beaker.
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Figure 3.4: Immersion of abamectin-exposed embryos in clean EM results in complete recovery of spontaneous activity relative to
vehicle-exposed embryos. Spontaneous activity (mean ± SD) during exposure to vehicle (0.1% DMSO) or 0.5 µM abamectin from 2327 hpf, with subsequent recovery in clean EM from 27-31 hpf. Asterisk (*) denotes significant difference in percent spontaneous
activity compared to within-treatment baseline (p<0.05). N = three replicate beakers per treatment and 20 initial embryos per replicate
beaker. Baseline reading was measured immediately prior to adding treatment solution. The dotted line indicates when embryos were
rinsed and transferred to clean EM.

Figure 3.5: Fipronil or endosulfan exposure from 5-25 hpf results in a decrease in
spontaneous activity at the highest concentrations tested in the absence of effects on
survival. (A, B) Survival (mean ± SD) or (C, D) spontaneous activity (mean ± SD) at 25
hpf following exposure to vehicle (0.1% DMSO), 3.125-25 µM fipronil or 0.625-5 µM
endosulfan from 5-25 hpf. Numbers above each bar denote mean percent spontaneous
activity. Asterisk (*) denotes significant difference in percent spontaneous activity from
vehicle control (p<0.05). N = three replicate beakers per treatment and 20 initial embryos
per replicate beaker.
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Figure 3.6: Abamectin-induced hypoactivity is blocked by pretreatment of embryos with
non-toxic concentrations of fipronil or endosulfan. (A, B) Survival (mean ± SD) and (B,
D) spontaneous activity (mean ± SD) at 25 hpf following exposure to vehicle (0.1%
DMSO) or 0.5 µM abamectin (23-25 hpf) with or without fipronil or endosulfan
pretreatment (5-23 hpf). Plus (+) or minus (-) signs indicate the presence or absence,
respectively, of a chemical for each treatment. Numbers above each bar denote mean
percent spontaneous activity. Asterisk (*) denotes significant difference in percent
spontaneous activity from vehicle control (p<0.05). N = three replicate beakers per
treatment and 20 initial embryos per replicate beaker.
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Figure 3.7: gabra1 and gabrb2 transcripts are present at 5, 10 and 23 hpf within normal
developing zebrafish embryos. Fold change data are mean ± SD relative to gabrb2 for
each developmental stage. Developmental stages that do not share the same letter are
significantly different (p < 0.05) from each other. N = three (10 hpf) or four (5 and 23
hpf) independent samples based on extracted RNA from replicate pools of 100 embryos
per pool.
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Figure 3.8: Phylogenetic analysis demonstrates that zebrafish ionotropic GABA receptor
(GABAAR) subunits are homologous to rodent and human ionotropic GABA receptor
subunits. Multiple alignment of all protein sequences (61 total) was conducted using
EMBL-EBI’s Clustal Omega, and alignment results were imported into EMBL-EBI’s
ClustalW2 Phylogeny to generate a phylogenetic tree.
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CHAPTER 4
CONCLUSIONS AND FUTURE RESEARCH
Within the United States, approximately one out of six children has a
developmental disability, most of which affect the nervous system

(Grandjean and

Landrigan, 2006). Treatment of neurodevelopmental disorders is difficult, and the
resulting disabilities may often be permanent and result in high damage and costs to
family and society. Moreover, in the last few decades, the observed increase in
neurodevelopmental disorders in children is thought to be partly due to increased
environmental exposure to potential neurotoxicants. In fact, roughly 3% of
neurodevelopmental disabilities may be due to exposure to environmental toxicants,
while 25% may arise due to gene-environment interactions (Giordano and Costa, 2012).
Although social factors are also believed to contribute to this increasing trend, there is
mounting evidence that demonstrates associations between environmental chemicals and
neurodevelopmental disorders. Consequently, DNT has now become an issue of growing
concern around the world, and the efforts of scientists and regulators are focused on
understanding the potential hazards of these chemical agents to help fill existing DNT
data gaps (National Research Council, 2000). As a result, there is general agreement
regarding the need to develop alternative test methods that are rapid and can be validated
and used across multiple laboratories. While these methods must not only help generate
reliable data that are predictive and effective, they should also accommodate screening
large numbers of chemicals. Therefore, developing a battery of HCS/HTS assays for
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DNT that emphasizes the use of alternative animal models and can be used within a
regulatory context is an important priority.
The first study (Chapter 2) demonstrated that HCS assays that rely on
neurobehavioral endpoints in zebrafish embryos can be used to 1) screen and prioritize
potential developmental neurotoxicants for further testing in other animal models and 2)
provide a foundation for developing hypothesis-driven mechanistic studies in zebrafish
embryos. For example, using the HCS assay described in Chapter 2, we identified two
chemicals - abamectin and emamectin benzoate – that significantly decreased
spontaneous activity in the absence of effects on survival and total body area. Although
spontaneous activity in zebrafish occurs a very early developmental stage (which cannot
be easily assessed in utero in mammals) and may not have direct phenotypic relevance to
rodent models or humans, these results can help predict potential neurotoxic effects of
chemicals that may have similar molecular targets in zebrafish and humans. In fact,
similar behavioral assays in zebrafish have been developed as ways to promote drug
discovery and even screen chemicals for neurotoxicity (Kokel et al., 2010).
Even though the HCS assay described in Chapter 2 was successful in identifying
potential developmental neurotoxicants during early zebrafish embryogenesis, the assay
had a few limitations. First, because spontaneous behavior is naturally variable and
occurs within a narrow time window during normal embryonic development, we were
only able to image 192 embryos (one well at a time) over an 80-minute time period using
a 2x objective. However, future research can begin to optimize the assay using a 1x
objective, which allows imaging of four wells together. Therefore, 384 embryos could be
imaged in just half the time (40 minutes) required to image 192 embryos using a 2x
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objective. This would also increase the sample size from 16 to 32 embryos per treatment
(one to two columns), allowing for multiple plates to be imaged per day. Ideally, this
would help control for the natural variation in spontaneous activity while also increasing
throughput.
Furthermore, the two positive hits identified in our screen had similar modes-ofaction, suggesting that this HCS assay may be biased towards identifying chemicals with
only specific neurotoxic modes-of-action, particularly at this early embryonic stage of
development. In addition, we only identified chemicals that resulted in hypo- rather than
hyper-activity. However, this initial screen comprised only a small subset of chemicals,
and the observed hit rate (1 out of 15, or 6.7%) is consistent with the hit rate of another
zebrafish behavioral screening assay (Kokel et al., 2010). In the future, increasing the
throughput of this assay would allow a larger battery of chemicals to be screened and
help determine whether this assay could potentially be used to group chemicals that share
common mechanisms of action and chemical structures (Kokel et al., 2010). Nonetheless,
these results support the use of this HCS assay to help identify potential developmental
neurotoxicants within a regulatory context.
The identification of abamectin as a potential developmental neurotoxicant led us
to develop hypothesis-driven studies to begin investigating the mechanism of abamectininduced hypoactivity. The second study (Chapter 3) demonstrated that 1) abamectin did
not affect outgrowth of spinal motoneurons, 2) abamectin-induced hypoactivity was rapid
and reversible, 3) abamectin-induced hypoactivity was blocked by pretreatment with two
GABA receptor antagonists, and 4) GABA receptor subunits within zebrafish and
mammals are homologous, suggesting that this has potential relevance to mammalian

74

systems. Based on the observed behavioral effect and known effects of GABA, we then
hypothesized that abamectin-induced hypoactivity occurs due to an influx of chloride
ions into interneurons, resulting in decreased membrane potential. However, initial
attempts within zebrafish embryos to assess voltage changes using the FLIPR assay were
unsuccessful. Future studies should rely on whole-cell patch clamp recording techniques
to assess voltage changes of zebrafish spinal cord neurons in vehicle and abamectinexposed embryos with or without addition of fipronil or endosulfan (GABA antagonists).
The addition of exogenous GABA should be used as a positive control in these studies. In
fact, the patch clamp technique has been used to successfully evaluate voltage changes of
interneurons, motoneurons, and sensory neurons in vivo within the spinal cord of 18-26
hpf zebrafish embryos (Saint-Amant and Drapeau, 2003).
In addition, it is still unclear whether abamectin-induced hypoactivity occurs by
direct chemical binding to the GABA receptor (as an agonist or antagonist), or by
stimulating production of GABA, which is then released into the presynaptic inhibitory
terminals (Novelli et al., 2012). Due to the rapid recovery of this behavior, we
hypothesize that abamectin potentiates the effect of GABA by binding to a site on GABA
receptors different from the active site. This would produce an effect similar to the
sedative, anxiolytic behavior observed with diazepam (Valium), a benzodiazepine drug
(Christian et al., 2013). Therefore, future studies should rely on 1) high-performance
liquid chromatography (HPLC) to quantify the amount of GABA neurotransmitter after
exposure to abamectin, 2) qPCR to determine whether genes involved in synthesizing or
transporting GABA are altered, and 3) ligand-binding assays. Together, these
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experiments would provide more detailed information about the mechanism of
abamectin-induced hypoactivity.
Additional follow-up studies could also be conducted to determine whether
abamectin exposure during early embryonic development has effects on other locomotive
behaviors, such as touch-response or swimming, potential long-term effects on cognition,
such as learning and memory, or multigenerational effects. Though our results suggest
that abamectin-induced hypoactivity is likely reversible, some industrial chemicals have
been found to exhibit “silent neurotoxicity” – a term that indicates the presence of
subclinical effects which are not monitored within health statistics. One example of this is
lead, a known developmental neurotoxicant, which is thought to affect IQ scores in the
absence of visible health effects, resulting in high economic costs to society (Grandjean
and Landrigan, 2006). Therefore, future work should aim to understand the effect of early
abamectin exposure on behavior and cognition at later stages (juvenile or adult) in order
to assess whether in utero exposure during early development has potential long-term
effects on the nervous system.
Finally, although zebrafish is a valuable in vivo model for understanding how
chemicals act within an intact organism, future in vitro studies using human cell lines
would complement these data, enhancing human relevance. In fact, there are numerous
human cell lines already available that are specific to the nervous system. For example,
human umbilical cord blood stem cells have been used to generate neural stem cell lines,
and human neural progenitor cells have been grown as neurospheres, allowing both the
embryonic and fetal periods of neurodevelopment to be explored in vitro (Bal-Price et al.,
2012; Smirnova et al., 2014). Neurospheres from different species can also be used to
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compare various toxicity endpoints across species (Smirnova et al., 2014). Recently,
human embryonic stem cells were even differentiated in vitro for DNT testing using
methylmercury (Bal-Price et al., 2012). Within a tiered testing strategy, the use of in vivo
data from zebrafish HCS/HTS assays or rodent models in combination with in vitro data
from human cell lines will help improve species extrapolation to humans. Moreover,
many imaging systems, including our ImageXpress Micro High-Content Imaging
System, already comprise established protocols to assess endpoints such as cell viability
and neurite outgrowth.
Overall, the work presented in this dissertation uses zebrafish as an alternative
animal model to help identify and prioritize chemicals for high-cost, low-throughput
DNT assays in rodent models, while also exploring the potential mechanism of action of
abamectin – a chemical identified as a positive hit in the HCS assay - within early
zebrafish embryos. Ultimately, a combination of assays with different endpoints will be
needed to effectively predict in vivo DNT, as assays in cell lines and small animal models
are not sufficient predictors of risk to humans on their own. The development of
HCS/HTS assays to screen and prioritize chemicals and the use of zebrafish for follow-up
mechanistic studies will reduce animal use as well as provide a means of defining hazard
for the thousands of chemicals in commerce with unknown toxicity data, helping fill the
current DNT data gaps. These data can then be used to help guide regulatory decisions
and support the registration of chemicals for use in commerce.
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APPENDIX A
HCS ASSAY OPTIMIZATION AND SUPPLEMENTAL DATA FOR SCREENING
Table A.1: Chemical name, chemical formula, CAS registry number, vendor, and purity
of all chemicals screened.
Chemical Name
Nicotine
Paraoxon
Rotenone
Thiram
Tefluthrin
Butafenacil
Pyridaben
Flumetralin
Fluthiacet-methyl
Abamectin
Fentin
Propargite
Milbemectin
Pyraclostrobin
(Z,E)Fenpyroximate
Tribufos
Famoxadone
Fluoxastrobin
Pyraflufen-ethyl
Trifloxystrobin
Emamectin benzoate

Chemical
Formula
C10H14N2
C10H14NO6P
C23H22O6
C6H12N2S4
C17H14ClF7O2
C20H18ClF3N2O6
C19H25ClN2OS
C16H12ClF4N3O4
C15H15ClFN3O3S2
C48H72O14 (B1a)
C47H70O14 (B1b)
C18H16OSn
C19H26O4S
C31H44O7
C19H18ClN3O4

CAS#

Vendor

54-11-5
311-45-5
83-79-4
137-26-8
79538-32-2
134605-64-4
96489-71-3
62924-70-3
117337-19-6

ChemService Inc.
ChemService Inc.
ChemService Inc.
ChemService Inc.
N/A
Sigma Aldrich
ChemService Inc.
ChemService Inc.
Sigma Aldrich

Purity
(%)
99.2
97.5
97.8
99.5
N/A
99.3
99.5
99.5
99.9

71751-41-2

ChemService Inc.

97.0

76-87-9
2312-35-8
51596-10-2
175013-18-0

ChemService Inc.
ChemService Inc.
N/A
ChemService Inc.

98.7
99.0
N/A
99.5

C24H27N3O4

134098-61-6

ChemService Inc.

99.5

C12H27OPS3
C22H18N2O4
C21H16ClFN4O5
C15H13Cl2F3N2O4
C20H19F3N2O4
C49H77NO13

78-48-8
131807-57-3
361377-29-9
129630-19-9
141517-21-7
155569-91-8

ChemService Inc.
ChemService Inc.
ChemService Inc.
ChemService Inc.
ChemService Inc.
ChemService Inc.

98.1
98.5
99.5
99.2
99.3
98.9

N/A = Not commercially available
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Table A.2: Optimized parameters for imaging spontaneous activity of 25-hpf fli1:egfp
zebrafish using an ImageXpress® Micro (IXM) Widefield High-Content Screening
System (Molecular Devices, Sunnyvale, CA).
Tab
Names and
Description
Objective and
Camera
Plate

Wells to visit
Sites to visit
Timelapse

Subset Tab 1

Subset Tab 2

Spontaneous Activity
Magnification

2x Plan Apo

Camera Binning
Gain
Matrical 0.17 mm glass
Number of rows
Well diameter (µm)
Column offset (µm)
Row offset (µm)
Number of columns
Column spacing (µm)
Row spacing (µm)
Well depth (µm)
Well shape
Plate length (mm)
Plate width (mm)
Plate height (mm)
192 of 384
Site Acquisition Option
Number of timepoints

2
Gain 1 (1x)

Perform time series for

Acquisition Loop

Interval
Duration
Number of wavelengths
Autofocus options (selected)

Autofocus

Well to well autofocus
Algorithm
Binning
Allow image-based focusing
for recovery from laser-
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16
2900
12000
9200
24
4490
4490
11500
Square
127.8
85.5
12.5
Single site
60
One well then
the next
0.1 sec
6 sec
1
Enable laserbased focusing
Enable imagebased focusing
Focus on plate
bottom, then
offset by
bottom
thickness
Standard
2

Subset Tab 3

based well bottom failures
Initial well for finding
sample
Number of wells to attempt
to initial find sample
Timelapse Autofocus
W1 FITC

Exposure

Autofocus options
Journals (2 selected)

Before each image
After each image

Display settings

Manually set image display
properties
Display images during
autofocus
Display images during
acquisition
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First well
acquired
1
First timepoint
only
Illumination
setting
Exposure (ms)
Target max
intensity
Laser with zoffset
Custom
Journal
Custom
Journal

FITC
10
3000
185.14 µm

Table A.3: Optimized parameters for analyzing spontaneous activity of 25-hpf fli1:egfp
zebrafish using EthoVision XT 9.0 (Noldus Information Technology, Leesburg, VA).
Tab
Setup

Subset Tab 1
Experiment
Settings

Subset Tab 2

Subset Tab 4

Unit of distance cm
Unit of time
Unit of rotation

Manual
Scoring
Settings
Arena
Settings

Subset Tab 3

s
deg

None
Arena 1
Calibration

Select the entire
well
Horizontal
Vertical

0.29 cm
0.29 cm

Validate arena
settings
Trial Control
Settings

Rule begin
Action
Action
Rule end

Detection
Settings

Trial List

Acquisition

Acquisition

Acquired
Trials

Method

Start-stop trial
(green circle)
Start track (green
triangle)
Stop track (red
square)
Start-stop trial
(red square)
Grey Scaling

Detection range (5-11) to 255
Video sample
10.0 per second
rate
Subject contour Contour erosion
Contour dilation
Add trials
192
Choose 192
Add videos
videos from
correct folder
Acquisition
Track all planned
setting
trials
Check “Detection
Acquisition
determines speed”
control
box
192 (after
acquisition)

90

1 pixel
1 pixel

To start trials,
click green
circle

Analysis

Data Profiles

Analysis
Profiles

Start box:
Selection
contains all 192
acquired tracks
Result 1 box:
Selection
contains 192
complete tracks
Mobility state
Outlier filter
Threshold

Results

Calculate
statistics for
Analysis
Output

Averaging
interval
Highly mobile
above
Highly mobile
Calculate
Export

Integrated
Visualization

Check trials
with active
embryos for
errors and
adjust manually
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4
8.40%

Table A.4: Image success rates for analysis of spontaneous activity and total body area
within control 25-hpf zebrafish embryos by column across three independent plates
containing an initial sample size of 192 embryos per plate.
Control
Plate

1

2

3

Live Embryos
Total Total
Column
(#)
(%)
1
16
100.0
3
16
100.0
5
16
100.0
7
16
100.0
9
16
100.0
11
16
100.0
13
16
100.0
15
16
100.0
17
16
100.0
19
16
100.0
21
16
100.0
23
16
100.0
1
15
93.8
3
16
100.0
5
15
93.8
7
16
100.0
9
16
100.0
11
16
100.0
13
16
100.0
15
16
100.0
17
15
93.8
19
14
87.5
21
15
93.8
23
15
93.8
1
16
100.0
3
16
100.0
5
16
100.0
7
16
100.0
9
16
100.0
11
16
100.0
13
16
100.0
15
16
100.0
17
16
100.0
19
16
100.0
21
16
100.0
23
16
100.0

Spontaneous Activity
Analyzed Analyzed
(#)
(%)
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
15
100.0
16
100.0
15
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
15
100.0
14
100.0
15
100.0
15
100.0
16
100.0
16
100.0
15
93.8
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
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Total Body Area
Analyzed Analyzed
(#)
(%)
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
15
100.0
16
100.0
15
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
15
100.0
14
100.0
14
93.3
15
100.0
16
100.0
16
100.0
15
93.8
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0
16
100.0

Table A.5: Summary of statistical results and overall effects on spontaneous activity for
all chemicals screened.

Nicotine

Vehicle
column 1
vs. 23
(p-value)
0.674

Main effect
of treatment
by column
(p-value)
0.090

Paraoxon

0.483

0.001

Rotenone

0.699

0.752

Thiram (high)

N/A

N/A

Thiram (low)

0.699

0.392

Tefluthrin

N/A

N/A

Butafenacil
Pyridaben
Flumetralin
Fluthiacetmethyl

0.164
1.000
0.472

0.113
0.106
0.097

0.422

0.716

Abamectin

0.723

0.000

Fentin

N/A

N/A

Propargite

0.050

0.027 ±

Milbemectin

N/A

N/A

Chemical

Treatment effects
compared to both Hypercolumns 1 and 23 active
(α = 0.05)
None
No
12.5 µM, 25 µM,
No
and 50 µM
None
No
Notochord
malformations in
N/A
all concentrations
tested
None
No
Not commercially
N/A
available
None
No
None
No
None
No
None
3.125 µM, 6.25
µM, 12.5 µM, 25
µM, and 50 µM
Insoluble in
DMSO
None
Not commercially
available
None

Hypoactive
No
Yes
No
N/A
No
N/A
No
No
No

No

No

No

Yes

N/A

N/A

No

No

N/A

N/A

Pyraclostrobin
0.588
0.804
No
No
(Z,E)0.821
0.492
None
No
No
Fenpyroximate
Tribufos
0.161
0.147
None
No
No
Famoxadone
0.133
0.572
None
No
No
Fluoxastrobin
0.857
0.492
None
No
No
Pyraflufen0.674
0.333
None
No
No
ethyl
Trifloxystrobin
0.782
0.171
None
No
No
Emamectin
0.111
0.001
25 µM and 50 µM
No
Yes
benzoate
±
0.39, 25, and 50 µM treatments significantly reduced spontaneous activity compared to
control column 23, but not control column 1
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94
Figure A.1: Spontaneous activity (%) following exposure to 50 µL embryo media from 5 to 25 hpf in a 384-well plate containing 384
initial embryos. Numbers above each bar denote percent spontaneous activity within that column.

95
Figure A.2: Flow diagram summarizing the exposure setup, image acquisition, and data extraction/analysis protocols for the HCS
assay. Using automated image acquisition protocols and parameters optimized for our ImageXpress® Micro Widefield High-Content
Screening System, each fli1:egfp embryo was imaged to assess the presence or absence of spontaneous tail contractions.

Figure A.3: Comparison of the number of tail flips predicted by EthoVision and the
number of tail flips counted manually within control 25-hpf zebrafish embryos across
three independent plates containing an initial sample size of 192 embryos per plate.
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Figure A.4: Frequency of spontaneous activity (%) per column across three independent
control plates with an initial size of 16 embryos per column and 12 columns per plate.
The lowest and highest percentages measured per column were 18.75 and 75%,
respectively.
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Figure A.5: Nicotine does not affect spontaneous activity in the absence of effects on
survival and total body area. Total body area data within each column are presented as
mean ± SD. N = final number of embryos analyzed per column. Numbers above each bar
denote percent spontaneous activity within that column. LC50 > 50 µM.
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Figure A.6: Rotenone does not affect spontaneous activity in the absence of effects on
survival and total body area. Based on control survival and total body area criteria,
hashed bars represent concentrations that were not analyzed for potential effects on
spontaneous activity. Absence of a bar denotes 0% survival. Total body area data within
each column are presented as mean ± SD. N = final number of embryos analyzed per
column. Asterisk denotes significant difference in total body area from both vehicle
controls (p<0.05). Numbers above each bar denote percent spontaneous activity within
that column. LC50 ≈ 0.37 µM.
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Figure A.7: Thiram (high) does not affect spontaneous activity in the absence of effects
on survival and total body area. Based on control survival and total body area criteria,
hashed bars represent concentrations that were not analyzed for potential effects on
spontaneous activity. Absence of a bar denotes 0% survival. Total body area data within
each column are presented as mean ± SD. N = final number of embryos analyzed per
column. Asterisk denotes significant difference in total body area from both vehicle
controls (p<0.05). Numbers above each bar denote percent spontaneous activity within
that column. LC50 ≈ 14.0 µM.
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Figure A.8: Thiram (low) does not affect spontaneous activity in the absence of effects
on survival and total body area. Based on control survival and total body area criteria,
hashed bars represent concentrations that were not analyzed for potential effects on
spontaneous activity. Total body area data within each column are presented as mean ±
SD. N = final number of embryos analyzed per column. Numbers above each bar denote
percent spontaneous activity within that column. LC50 ≈ 14.0 µM.
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Figure A.9: Butafenacil does not affect spontaneous activity in the absence of effects on
survival and total body area. Total body area data within each column are presented as
mean ± SD. N = final number of embryos analyzed per column. Numbers above each bar
denote percent spontaneous activity within that column. LC50 > 50 µM.
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Figure A.10: Pyridaben does not affect spontaneous activity in the absence of effects on
survival and total body area. Based on control survival and total body area criteria,
hashed bars represent concentrations that were not analyzed for potential effects on
spontaneous activity. Absence of a bar denotes 0% survival. Total body area data within
each column are presented as mean ± SD. N = final number of embryos analyzed per
column. Asterisk denotes significant difference in total body area from both vehicle
controls (p<0.05). Numbers above each bar denote percent spontaneous activity within
that column. LC50 ≈ 1.1 µM.
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Figure A.11: Flumetralin does not affect spontaneous activity in the absence of effects
on survival and total body area. Total body area data within each column are presented as
mean ± SD. N = final number of embryos analyzed per column. Numbers above each bar
denote percent spontaneous activity within that column. LC50 > 50 µM.
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Figure A.12: Fluthiacet-methyl does not affect spontaneous activity in the absence of
effects on survival and total body area. Based on control survival and total body area
criteria, hashed bars represent concentrations that were not analyzed for potential effects
on spontaneous activity. Absence of a bar denotes 0% survival. Total body area data
within each column are presented as mean ± SD. N = final number of embryos analyzed
per column. Asterisk denotes significant difference in total body area from both vehicle
controls (p<0.05). Numbers above each bar denote percent spontaneous activity within
that column. LC50 ≈ 30.1 µM.
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Figure A.13: Propargite does not affect spontaneous activity in the absence of effects on
survival and total body area. Total body area data within each column are presented as
mean ± SD. N = final number of embryos analyzed per column. Numbers above each bar
denote percent spontaneous activity within that column. LC50 >50 µM.
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Figure A.14: Pyraclostrobin does not affect spontaneous activity in the absence of effects
on survival and total body area. Based on control survival and total body area criteria,
hashed bars represent concentrations that were not analyzed for potential effects on
spontaneous activity. Absence of a bar denotes 0% survival. Total body area data within
each column are presented as mean ± SD. N = final number of embryos analyzed per
column. Asterisk denotes significant difference in total body area from both vehicle
controls (p<0.05). Numbers above each bar denote percent spontaneous activity within
that column. LC50 ≈ 1.8 µM.
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Figure A.15: (Z,E)-Fenpyroximate does not affect spontaneous activity in the absence of
effects on survival and total body area. Based on control survival and total body area
criteria, hashed bars represent concentrations that were not analyzed for potential effects
on spontaneous activity. Absence of a bar denotes 0% survival. Total body area data
within each column are presented as mean ± SD. N = final number of embryos analyzed
per column. Asterisk denotes significant difference in total body area from both vehicle
controls (p<0.05). Numbers above each bar denote percent spontaneous activity within
that column. LC50 ≈ 0.8 µM.
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Figure A.16: Tribufos does not affect spontaneous activity in the absence of effects on
survival and total body area. Total body area data within each column are presented as
mean ± SD. N = final number of embryos analyzed per column. Numbers above each bar
denote percent spontaneous activity within that column. LC50 > 50 µM.
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Figure A.17: Famoxadone does not affect spontaneous activity in the absence of effects
on survival and total body area. Based on control survival and total body area criteria,
hashed bars represent concentrations that were not analyzed for potential effects on
spontaneous activity. Absence of a bar denotes 0% survival. Total body area data within
each column are presented as mean ± SD. N = final number of embryos analyzed per
column. Asterisk denotes significant difference in total body area from both vehicle
controls (p<0.05). Numbers above each bar denote percent spontaneous activity within
that column. LC50 ≈ 3.3 µM.
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Figure A.18: Fluoxastrobin does not affect spontaneous activity in the absence of effects
on survival and total body area. Based on control survival and total body area criteria,
hashed bars represent concentrations that were not analyzed for potential effects on
spontaneous activity. Absence of a bar denotes 0% survival. Total body area data within
each column are presented as mean ± SD. N = final number of embryos analyzed per
column. Numbers above each bar denote percent spontaneous activity within that
column. LC50 ≈ 5.8 µM.
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Figure A.19: Pyraflufen-ethyl does not affect spontaneous activity in the absence of
effects on survival and total body area. Total body area data within each column are
presented as mean ± SD. N = final number of embryos analyzed per column. Numbers
above each bar denote percent spontaneous activity within that column. LC50 > 50 µM.
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Figure A.20: Trifloxystrobin does not affect spontaneous activity in the absence of
effects on survival and total body area. Based on control survival and total body area
criteria, hashed bars represent concentrations that were not analyzed for potential effects
on spontaneous activity. Absence of a bar denotes 0% survival. Total body area data
within each column are presented as mean ± SD. N = final number of embryos analyzed
per column. Asterisk denotes significant difference in total body area from both vehicle
controls (p<0.05). Numbers above each bar denote percent spontaneous activity within
that column. LC50 ≈ 2.6 µM.
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APPENDIX B
MECHANISTIC STUDIES WITH ABAMECTIN
B.1 MATERIALS AND METHODS
B.1.1 CHEMICALS
Bicuculline, picrotoxin and strychnine were purchased from ChemService, Inc.
(West Chester, PA). All stock and working solutions were prepared as described in
Chapter 3, Section 3.2.2.

B.1.2 PRETREATMENT

OF ZEBRAFISH EMBRYOS WITH LIGAND-GATED CHLORIDE CHANNEL

ANTAGONISTS

We used bicuculline and picrotoxin - two commercially available GABA receptor
antagonists - and strychnine – a rodenticide that antagonizes the glycine receptor - to test
whether abamectin-induced hypoactivity was mediated through GABA or glycine
receptors. To identify the maximum tolerated concentration that did not adversely impact
spontaneous activity, range-finding exposures for bicuculline (3.125-25 µM), picrotoxin
(0.625-5 µM), and strychnine (0.39-3.125) alone were first conducted under static
exposure conditions in 50 mL beakers as described in Chapter 3, Section 3.2.3. Based on
these range-finding exposures, the final no-effect concentration used for these
experiments was 12.5 µM, 1.25 µM, and 3.125 µM for bicuculline, picrotoxin, and
strychnine, respectively. Then, pretreatment exposures were conducted as described in
Chapter 3, Section 3.2.5.
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B.1.3 IN SITU ASSESSMENT OF GABA WITHIN 25-HPF ZEBRAFISH EMBRYOS
Wildtype (5D) embryos were exposed in triplicate glass beakers to either vehicle
(0.1% DMSO) or 0.5 µM abamectin from 5-25 hpf at 28°C. Live embryos were then
dechorionated by incubating embryos in 0.5 mg/mL pronase for 20 min on a shaker at
100 rpm. Embryos were then washed in RO water and fixed overnight in 4%
paraformaldehyde. Fixed embryos were permeabilized by incubating in cold acetone at 20°C for 15 minutes, and then rinsed four times in phosphate-buffered saline (PBS)/0.1%
Tween-20 (PBST) for 5 min per wash. Permeabilized embryos were incubated in fresh
blocking buffer (PBST/2% sheep serum/2 mg/ml bovine serum albumin) for 4 hours at
room temperature with gentle agitation, and then incubated overnight at 4°C with gentle
agitation in blocking buffer containing a 1:20 dilution of znp-1 IgG2a (Invitrogen) and a
1:500 dilution of anti-GABA (Sigma Aldrich). znp-1 IgG2a is a zebrafish-specific
antibody that recognizes cell bodies and axons of primary motoneurons in 25-hpf
zebrafish (Pike et al., 1992; Trevarrow et al., 1990). Following primary antibody
incubation, embryos were washed five times with gentle agitation in PBST at room
temperature for 15 minutes each. Embryos were incubated overnight at 4°C with gentle
agitation in blocking buffer containing a 1:500 dilution of Alexa Fluor 488 (AF488)conjugated goat anti-mouse (Invitrogen) to visualize znp-1 localization in situ and a
1:2000 dilution of Alexa Fluor 555 (AF555-conjugated goat anti-rabbit (H+L)
(Invitrogen) to visualize anti-GABA localization in situ. Finally, secondary antibodylabeled embryos were washed five times with gentle agitation in PBST at room
temperature for 15 minutes each, and then stored in PBS at 4°C until imaging. Labeled
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embryos were imaged at 10X magnification using a FITC or TRITC filter cube and
Olympus BX51 Research System Microscope equipped with an Olympus DP72 Digital
Color Camera and Olympus DP2-BSW Imaging Software.

B.1.4 WHOLE MOUNT IN SITU HYBRIDIZATION
To localize gabra1 transcripts within developing zebrafish embryos, whole-mount
in situ hybridization was performed as previously described (Thisse and Thisse, 2008).
The following PCR primers were used to amplify a 1020-bp gabra1 fragment: forward
primer 5’-TGCGATACATTCCGGGTGAG-3’, reverse primer 5’-GGGAGAGAGT
TTCTTGCGCT-3’. Per manufacturer’s instructions, a 1020-bp gabra1 fragment was
PCR-amplified from approximately 100 ng of cDNA using GoTaq Hot Start Green
Master Mix (Promega) and the following PCR reaction conditions: 2 minutes at 95°C
followed by 35 cycles of 95°C for 30 seconds, 52°C for 30 seconds, and 72°C for 90
seconds, with a final extension step at 72°C for 5 minutes. Amplified 1020-bp gabra1
fragments were then gel purified and ligated into pGEM-T Easy Vector System
(Promega). JM109 Competent Cells (Promega) were transformed with the resulting
vector and plasmids were purified from transformed colonies using a PureYield Plasmid
Miniprep System (Promega). Per manufacturer’s instructions, RNA probes were
developed using a Digoxigenin (DIG) RNA Labeling Kit (Roche Applied Science,
Indianapolis, IN). For antisense hybridizations, purified plasmid was linearized with NcoI
(New England Biolabs, Ipswich, MA), and SP6 polymerase was used to develop DIGlabeled antisense gabra1 RNA probes. To assess the specificity of gabra1-specific
antisense probes, purified plasmid was linearized with SalI (New England Biolabs), and
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T7 polymerase was used to develop DIG-labeled sense (negative control) gabra1 RNA
probes. Antisense and sense RNA probes were purified using illustraProbeQuant G-50
Micro Columns (GE Healthcare, Piscataway, NJ).
Embryos representing three developmental stages (5, 10, and 23 hpf) were
dechorionated by incubating embryos in 0.5 mg/mL pronase for 20 min on a shaker at
100 rpm. Embryos were then rinsed in RO water and fixed in 4% paraformaldehyde/PBS
overnight at 4°C. Fixed embryos were then dehydrated in 100% methanol (MeOH) for 15
min at room temperature and stored at -20°C until in situ hybridization procedures.
Dehydrated embryos were rehydrated with 75, 50, and 25% MeOH/PBS and then rinsed
with PBS containing 0.1% Tween-20 (PBST). Embryos were permeabilized with
proteinase K (10 µg/mL), refixed with 4% paraformaldehyde/PBS for 20 minutes, and
then washed four times with PBST. Embryos were prehybridized with 700 µL of
hybridization mixture (HM) (50% deionized formamide; 5x saline sodium citrate (SSC);
0.1% Tween-20; 50 µg/mL heparin; 150 µg/mL RNase-free transfer RNA (tRNA); pH
6.0) for 3.5 hours in a 45°C water bath. Prehybridized embryos were then hybridized
overnight at 45°C in 200 µL of HM containing 50 ng of DIG-labeled sense or antisense
gabra1 RNA probe. Following hybridization, embryos were thoroughly washed with HM
(without heparin and RNase-free tRNA), SSC, and PBST. Embryos were incubated for
3.5 hours at room temperature in blocking buffer (PBST; 2% sheep serum; 2 mg/mL
bovine serum albumin). Embryos were then either:
1) Incubated overnight at 4°C in alkaline phosphatase-conjugated sheep anti-DIG
Fab fragments diluted 1:4000 with blocking buffer. Antibody-labeled embryos
were then washed with PBST and alkaline Tris buffer, and DIG localization
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visualized with a nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl
phosphate (NBT/BCIP) substrate solution (Roche Applied Science). Following
color development, embryos were incubated within stop solution (13 PBS; 1mM
EDTA; 0.1% Tween-20; pH 5.5) to terminate enzymatic reactions.
2) Incubated overnight in the dark at 4°C in Anti-DIG Flourescein diluted 1:200
with blocking buffer. Antibody-labeled embryos were then washed with PBST.
All embryos were imaged using an Olympus BX51 Research System Microscope
equipped with an Olympus DP72 Digital Color Camera and Olympus DP2-BSW Imaging
Software.

B.1.5 FLUORESCENT IMAGING PLATE READER (FLIPR) MEMBRANE POTENTIAL ASSAY
To evaluate changes in membrane potential, we used the FLIPR Membrane
Potential Assay Kit (Molecular Devices). Fli1:egfp embryos (20 per beaker) were first
incubated in 1x EM until 22 hpf, then incubated in a 1:1 ratio of 1x EM to Red Assay
Reagent for 1 hour at room temperature in the dark. Live embryos were then washed
twice with 1x EM and exposed to either vehicle (0.1% DMSO) or 0.5 µM abamectin
from 23-25 hpf in the dark at room temperature. At 25 hpf, embryos were imaged using a
TRITC filter cube to assess fluorescence within the embryos and an Olympus MVX10
MacroView stereomicroscope equipped with an Olympus DP72 Digital Color Camera
and Olympus DP2-BSW Imaging Software.
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B.2 RESULTS
B.2.1 PRETREATMENT

OF ZEBRAFISH EMBRYOS WITH LIGAND-GATED CHLORIDE CHANNEL

ANTAGONISTS

Based on initial range-finding exposures with bicuculline, picrotoxin, and
strychnine, we selected 12.5 µM, 250 µM, and 3.125 µM of bicuculline, picrotoxin and
strychnine, respectively, as the maximum tolerated concentration based on the absence of
effects on spontaneous activity. In pretreatment experiments with bicuculline, picrotoxin,
and strychnine, average survival within all exposure groups was ≥95%. Spontaneous
activity within vehicle controls was at least 79% and hypoactivity was observed within
abamectin-exposed embryos pretreated with vehicle, bicuculline (Figure B.1), picrotoxin
(Figure B.2), or strychnine (Figure B.3). Therefore, abamectin-induced hypoactivity was
not blocked by pretreatment with non-toxic concentrations of these commercial GABA
receptor antagonists or glycine receptor antagonist. Due to the high water solubility of the
GABA receptor antagonists, it is thought that this lack of effect may be due to limited to
no embryonic uptake. However, strychnine is a fairly hydrophobic compound and was
likely taken up by the embryos, suggesting that abamectin-induced hypoactivity is not
mediated through the glycine receptor.

B.2.2 IN SITU ASSESSMENT OF GABA WITHIN 25-HPF ZEBRAFISH EMBRYOS
To assess the presence of GABA in situ within 25-hpf zebrafish embryos, we used
whole-mount immunohistochemistry. GABAergic neurons were detected within the
spinal cord of both vehicle and abamectin-exposed embryos, but not in the primary
motoneurons. However, no detectable differences were observed when comparing the
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two treatments (Figure B.4) and there was a lot of individual embryo variation. Due to
the background GABA staining in the trunk musculature it was difficult to assess the
specificity of GABA localization in situ.

B.2.3 WHOLE-MOUNT IN SITU HYBRIDIZATION
To assess the spatiotemporal distribution of gabra1 expression, we conducted
whole-mount in situ hybridization at 25 hpf using sense and antisense probes against
gabra1 mRNA. However, attempts to use colorimetric and fluorescent detection were
unsuccessful and we were unable to determine gabra1 localization.

B.2.4 FLIPR MEMBRANE POTENTIAL ASSAY
To assess voltage changes within zebrafish embryos after exposure to vehicle or
abamectin, we used a fluorescence-based assay that detects changes in ion channel
modulation through increases or decreases in the fluorescent signal as cellular membrane
potential changes. During membrane depolarization, indicator dye follows the positively
charged ions resulting in increased cellular fluorescence. During hyperpolarization,
fluorescence intensity decreases due to the indicator dye following positive ions out of
the cell. After incubation with Red Assay Reagent and subsequent exposure to vehicle or
abamectin, no detectable differences in fluorescence were observed when comparing the
two treatments (Figure B.5). Although we expected to see lower fluorescence in
abamectin-exposed embryos due to hyperpolarization, this assay was designed for
imaging cell lines in real-time, and likely requires further optimization in zebrafish.
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Figure B.1: Abamectin-induced hypoactivity is not blocked by pretreatment of embryos
with non-toxic concentrations of bicuculline. (A) Survival and (B) spontaneous activity at
25 hpf following exposure to vehicle (0.1% DMSO) or 0.5 µM abamectin (23-25 hpf)
with or without bicuculline pre-treatment (5-23 hpf). Plus (+) or minus (-) signs indicate
the presence or absence, respectively, of a chemical for each treatment. Numbers above
each bar denote percent spontaneous activity. Asterisk (*) denotes significant difference
in percent spontaneous activity from vehicle control (p<0.05). N = 20 initial embryos per
beaker.
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Figure B.2: Abamectin-induced hypoactivity is not blocked by pretreatment of embryos
with non-toxic concentrations of picrotoxin. (A) Survival and (B) spontaneous activity at
25 hpf following exposure to vehicle (0.1% DMSO) or 0.5 µM abamectin (23-25 hpf)
with or without picrotoxin pre-treatment (5-23 hpf). Plus (+) or minus (-) signs indicate
the presence or absence, respectively, of a chemical for each treatment. Numbers above
each bar denote percent spontaneous activity. Asterisk (*) denotes significant difference
in percent spontaneous activity from vehicle control (p<0.05). N = 20 initial embryos per
beaker.
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Figure B.3: Abamectin-induced hypoactivity is not blocked by pretreatment of embryos
with non-toxic concentrations of strychnine. (A) Survival and (B) spontaneous activity at
25 hpf following exposure to vehicle (0.1% DMSO) or 0.5 µM abamectin (23-25 hpf)
with or without strychnine pre-treatment (5-23 hpf). Plus (+) or minus (-) signs indicate
the presence or absence, respectively, of a chemical for each treatment. Numbers above
each bar denote percent spontaneous activity. Asterisk (*) denotes significant difference
in percent spontaneous activity from vehicle control (p<0.05). N = 20 initial embryos per
beaker.
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Figure B.4: Fixed wildtype (5D) embryos exposed to vehicle (0.1% DMSO) or
abamectin (0.5 µM) from 5-25 hpf and incubated in znp-1 and anti-GABA antibody
overnight at 4°C followed by an overnight incubation in goat anti-mouse IgG2a Alexa
Fluor 488 and goat anti-rabbit IgG (H+L) Alexa Fluor 555.
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Figure B.5: Fli1:egfp embryos incubated in Red Assay Reagent and then exposed to
vehicle (0.1% DMSO) or abamectin (0.5 µM) from 23-25 hpf. Images were taken using a
TRITC filter cube and no difference in fluorescence was observed when comparing the
two treatments.
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